<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001446.pub5" GROUP_ID="NEUROMUSC" ID="357899071916480444" MERGED_FROM="" MODIFIED="2016-10-04 10:23:10 +0100" MODIFIED_BY="Ruth Brassington" REVIEW_NO="001" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="15.0">
<COVER_SHEET MODIFIED="2016-10-04 10:22:44 +0100" MODIFIED_BY="Ruth Brassington">
<TITLE>Corticosteroids for Guillain-Barré syndrome</TITLE>
<CONTACT MODIFIED="2016-10-04 10:22:44 +0100" MODIFIED_BY="Ruth Brassington"><PERSON ID="7655" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Richard</FIRST_NAME><MIDDLE_INITIALS>AC</MIDDLE_INITIALS><LAST_NAME>Hughes</LAST_NAME><SUFFIX>MD FRCP FMedSci</SUFFIX><POSITION>Professor of Neurology</POSITION><EMAIL_1>rhughes11@btinternet.com</EMAIL_1><EMAIL_2>richard.hughes@ucl.ac.uk</EMAIL_2><ADDRESS><DEPARTMENT>MRC Centre for Neuromuscular Diseases</DEPARTMENT><ORGANISATION>National Hospital for Neurology and Neurosurgery</ORGANISATION><ADDRESS_1>PO Box 114</ADDRESS_1><ADDRESS_2>Queen Square</ADDRESS_2><CITY>London</CITY><ZIP>WC1N 3BG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7676 2060</PHONE_1><FAX_1>+44 20 7829 8725</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-10-04 10:22:44 +0100" MODIFIED_BY="Ruth Brassington"><PERSON ID="7655" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Richard</FIRST_NAME><MIDDLE_INITIALS>AC</MIDDLE_INITIALS><LAST_NAME>Hughes</LAST_NAME><SUFFIX>MD FRCP FMedSci</SUFFIX><POSITION>Professor of Neurology</POSITION><EMAIL_1>rhughes11@btinternet.com</EMAIL_1><EMAIL_2>richard.hughes@ucl.ac.uk</EMAIL_2><ADDRESS><DEPARTMENT>MRC Centre for Neuromuscular Diseases</DEPARTMENT><ORGANISATION>National Hospital for Neurology and Neurosurgery</ORGANISATION><ADDRESS_1>PO Box 114</ADDRESS_1><ADDRESS_2>Queen Square</ADDRESS_2><CITY>London</CITY><ZIP>WC1N 3BG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7676 2060</PHONE_1><FAX_1>+44 20 7829 8725</FAX_1></ADDRESS></PERSON><PERSON ID="9D90184382E26AA200C3FEB648B5FC66" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ruth</FIRST_NAME><LAST_NAME>Brassington</LAST_NAME><POSITION>Managing Editor</POSITION><EMAIL_1>cochranenmd@ion.ucl.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>MRC Centre for Neuromuscular Diseases</DEPARTMENT><ORGANISATION>National Hospital for Neurology and Neurosurgery</ORGANISATION><ADDRESS_1>PO Box 114</ADDRESS_1><CITY>London</CITY><ZIP>WC1N 3BG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0)203 448 8134</PHONE_1><FAX_1>+44 (0)203 448 4725</FAX_1></ADDRESS></PERSON><PERSON ID="7565" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Angela A</FIRST_NAME><LAST_NAME>Gunn</LAST_NAME><POSITION>Information Specialist, Cochrane Neuromuscular Group</POSITION><EMAIL_1>ion.nmdgrouptsc@ucl.ac.uk</EMAIL_1><EMAIL_2>angela.gunn@ucl.ac.uk</EMAIL_2><ADDRESS><DEPARTMENT>MRC Centre for Neuromuscular Diseases</DEPARTMENT><ORGANISATION>National Hospital for Neurology and Neurosurgery</ORGANISATION><ADDRESS_1>PO Box 114</ADDRESS_1><CITY>London</CITY><ZIP>WC1N 3BG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 203 448 8133</PHONE_1><FAX_1>+44 20 3448 4725</FAX_1></ADDRESS></PERSON><PERSON ID="15454" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Pieter</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>van Doorn</LAST_NAME><POSITION>Neurologist</POSITION><EMAIL_1>p.a.vandoorn@erasmusmc.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Erasmus University Medical Center</ORGANISATION><ADDRESS_1>PO Box 2040</ADDRESS_1><CITY>Rotterdam</CITY><ZIP>3000 CA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+ 31 10 703 5747</PHONE_1><FAX_1>+ 31 10 703 5927</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2016-04-27 12:44:21 +0100" MODIFIED_BY="Richard Hughes">
<UP_TO_DATE>
<DATE DAY="12" MONTH="1" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="12" MONTH="1" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="12" MONTH="1" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="1999"/>
<LAST_CITATION_ISSUE ISSUE="10" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-08-08 15:06:46 +0100" MODIFIED_BY="KLJ ">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-08-08 15:06:46 +0100" MODIFIED_BY="KLJ ">
<DATE DAY="18" MONTH="1" YEAR="2016"/>
<DESCRIPTION>
<P>No new RCTs identified. Ruth Brassington and Angela Gunn became authors.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-08-08 15:06:46 +0100" MODIFIED_BY="KLJ ">
<DATE DAY="18" MONTH="1" YEAR="2016"/>
<DESCRIPTION>
<P>New EMBASE filter used, CENTRAL and Cochrane Neuromuscular Specialised Register searches run via the CRSO &amp; CRS</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-08-08 15:06:52 +0100" MODIFIED_BY="KLJ ">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-05-11 14:49:30 +0100" MODIFIED_BY="Ruth  Brassington">
<DATE DAY="4" MONTH="4" YEAR="2012"/>
<DESCRIPTION>
<P>New search incorporated. Dr AV Swan retired from authorship.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-05-11 14:49:26 +0100" MODIFIED_BY="Ruth  Brassington">
<DATE DAY="17" MONTH="2" YEAR="2012"/>
<DESCRIPTION>
<P>No trials found, minor changes to text.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-04-04 13:28:23 +0100" MODIFIED_BY="Ruth Brassington">
<DATE DAY="20" MONTH="1" YEAR="2010"/>
<DESCRIPTION>
<P>Dr R van Koningsveld retired from authorship.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-08-08 15:06:52 +0100" MODIFIED_BY="KLJ ">
<DATE DAY="10" MONTH="6" YEAR="2009"/>
<DESCRIPTION>
<P>New search to June 2009: no new trials found. New MEDLINE filter used.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-01-20 12:31:30 +0000" MODIFIED_BY="Ruth Brassington">
<DATE DAY="22" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-07-22 20:53:34 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="28" MONTH="2" YEAR="2007"/>
<DESCRIPTION>
<P>The searches were updated in February 2007, but no new studies were identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2008-07-22 21:02:46 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="31" MONTH="1" YEAR="2006"/>
<DESCRIPTION>
<P>A large trial has been added almost doubling the amount of evidence. This trial showed a trend towards more improvement on short-term benefit which became significant after taking into account prognostic factors that were imbalanced between the groups at randomisation. This did not alter the conclusion of the meta-analysis from all trials that corticosteroids do not produce significant benefit.<BR/>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-07-22 20:58:11 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="10" YEAR="1999"/>
<DESCRIPTION>
<P>An error in entering the standard deviations for change in disability grade after one year for the trial of Hughes 1978, has been corrected in the table of comparisons. This has resulted in the difference between the groups becoming not significant for that outcome, in agreement with the other outcome measures.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2016-10-04 09:53:57 +0100" MODIFIED_BY="Ruth Brassington">
<INTERNAL_SOURCES MODIFIED="2016-10-04 09:53:57 +0100" MODIFIED_BY="Ruth Brassington">
<SOURCE MODIFIED="2009-10-12 17:37:10 +0100" MODIFIED_BY="Ruth Brassington">
<NAME>King's College, London</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Infrastructure</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2009-10-12 17:36:59 +0100" MODIFIED_BY="Ruth Brassington">
<NAME>University College London</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Infrastructure</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2009-10-05 13:02:12 +0100" MODIFIED_BY="Richard Hughes">
<NAME>Erasmus Medical Centre Rotterdam</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION>
<P>Infrastructure</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2016-10-04 09:53:57 +0100" MODIFIED_BY="Ruth Brassington">
<NAME>National Institute of Health Research (NIHR)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Salary of Angela Gunn and Ruth Brassington at University College London NHS Foundation Trust is paid from NIHR Cochrane Infrastructure funding to Cochrane Neuromuscular</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Guillain-Barré Syndrome Foundation International</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-10-03 15:54:26 +0100" MODIFIED_BY="Ruth Brassington">
<SUMMARY MODIFIED="2016-10-03 15:27:59 +0100" MODIFIED_BY="Ruth Brassington">
<TITLE MODIFIED="2009-12-11 14:27:58 +0000" MODIFIED_BY="Ruth Brassington" NOTES="&lt;p&gt;needs to be edited to conform with 2016 house style: Ruth to provide headings&lt;/p&gt;" NOTES_MODIFIED="2009-12-11 14:27:58 +0000" NOTES_MODIFIED_BY="Ruth Brassington">Corticosteroids for Guillain-Barré syndrome</TITLE>
<SUMMARY_BODY MODIFIED="2016-10-03 15:26:42 +0100" MODIFIED_BY="Ruth Brassington" NOTES="&lt;p&gt;'there was a trend towards more benefit from intravenous corticosteroids in improvement in disability after four weeks but this trend was not significant'.&lt;/p&gt;&lt;p&gt;We are not supposed to say 'a trend towards' for effects that are not significant&lt;/p&gt;" NOTES_MODIFIED="2016-10-03 15:26:42 +0100" NOTES_MODIFIED_BY="Ruth Brassington">
<P>
<B>Review question</B>
</P>
<P>Do corticosteroids hasten recovery from disability in people with Guillain-Barré syndrome compared with dummy (placebo) treatment or supportive care alone?</P>
<P>
<B>Background</B>
</P>
<P>Guillain-Barré syndrome is an uncommon paralysing illness, usually caused when the person's immune system attacks their own nerves, which consequently become inflamed. In 25% of people affected, the disease leads to a need for artificial ventilation. About 5% of people with the disease die and about 10% are left disabled. Corticosteroids (such as prednisolone) reduce inflammation and so should reduce nerve damage.</P>
<P>
<B>Study characteristics </B>
</P>
<P>There were eight clinical trials with altogether 653 participants. Only six trials with altogether 587 participants gave information about the primary outcome measure for this review, which was change in a seven-point disability scale. Financial support came from Baxter Bioscience for one trial, research councils for two trials, the National Institutes of Health for one trial, and unstated sources for the others.</P>
<P>
<B>Key results and quality of the evidence</B>
</P>
<P>According to moderate quality evidence, when we pooled the results of the six trials with the necessary information there was no significant difference in change in disability grade after four weeks. Also according to moderate quality evidence, there was no difference in the percentage of participants who died or were left disabled after one year. We considered the evidence about disability unreliable because of marked variations between the trials. In four small trials of oral corticosteroids, with 120 participants, there was significantly less improvement after four weeks with corticosteroids than without corticosteroids but we considered the evidence quality very low. By contrast, according to moderate quality evidence, in two large trials of intravenous (injected into a vein) corticosteroids with a combined total of 467 participants, there was a slight improvement in disability after four weeks, but the results allowed for the possibility of no effect. Corticosteroids were not associated with a significant increase in harm except that diabetes was significantly more common than with placebo or supportive treatment alone. Although high blood pressure is a known harmful effect of corticosteroids, high blood pressure was unexpectedly much less common in the corticosteroid-treated participants. The lack of benefit from corticosteroids is not understood but might be because the drugs have a harmful effect on muscles which counteracts the benefit from reducing inflammation in nerves.</P>
<P>The review is assessed as up to date to January 2016.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-10-03 15:18:32 +0100" MODIFIED_BY="Ruth Brassington">
<ABS_BACKGROUND MODIFIED="2012-06-12 09:41:26 +0100" MODIFIED_BY="Ruth Brassington">
<P>Guillain-Barré syndrome (GBS) is an acute paralysing disease caused by inflammation of the peripheral nerves, which corticosteroids would be expected to benefit.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-06-12 09:41:28 +0100" MODIFIED_BY="Ruth Brassington">
<P>To examine the ability of corticosteroids to hasten recovery and reduce the long-term morbidity from GBS.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-10-03 15:18:15 +0100" MODIFIED_BY="Ruth Brassington">
<P>On 12 January 2016, we searched the Cochrane Neuromuscular Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and Embase. We also searched trials registries.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-08-08 15:08:03 +0100" MODIFIED_BY="KLJ ">
<P>We included randomised controlled trials (RCTs) or quasi-RCTs of any form of corticosteroid or adrenocorticotrophic hormone versus placebo or supportive care alone in GBS. Our primary outcome was change in disability grade on a seven-point scale after four weeks. Secondary outcomes included time from randomisation until recovery of unaided walking, time from randomisation until discontinuation of ventilation (for those ventilated), death, death or disability (inability to walk without aid) after 12 months, relapse, and adverse events.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-08-08 15:08:24 +0100" MODIFIED_BY="KLJ ">
<P>The review authors used standard methods expected by Cochrane.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-10-03 15:18:30 +0100" MODIFIED_BY="Ruth Brassington">
<P>The review authors discovered no new trials in the new searches in June 2009, November 2011, or January 2016. Six trials with 587 participants provided data for the primary outcome. According to moderate quality evidence, the disability grade change after four weeks in the corticosteroid groups was not significantly different from that in the control groups, mean difference (MD) 0.36 less improvement (95% confidence intervals (CI) 0.16 more to 0.88 less improvement). In four trials of oral corticosteroids with 120 participants in total, there was very low quality evidence of less improvement after four weeks with corticosteroids than without corticosteroids, MD 0.82 disability grades less improvement (95% CI 0.17 to 1.47 grades less). In two trials with a combined total of 467 participants, there was moderate quality evidence of no significant difference of a disability grade more improvement after four weeks with intravenous corticosteroids (MD 0.17, 95% CI -0.06 to 0.39). According to moderate quality evidence, there was also no significant difference between the corticosteroid treated and control groups for improvement by one or more grades after four weeks (risk ratio (RR) 1.08, 95% CI 0.93 to 1.24) or for death or disability after one year (RR 1.51, 95% CI 0.91 to 2.5). We found high quality evidence that the occurrence of diabetes was more common (RR 2.21, 95% CI 1.19 to 4.12) and hypertension less common (RR 0.15, 95% CI 0.05 to 0.41) in the corticosteroid-treated participants.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-10-03 15:18:32 +0100" MODIFIED_BY="Ruth Brassington">
<P>According to moderate quality evidence, corticosteroids given alone do not significantly hasten recovery from GBS or affect the long-term outcome. According to very low quality evidence, oral corticosteroids delay recovery. Diabetes requiring insulin was more common and hypertension less common with corticosteroids based on high quality evidence.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-10-03 15:27:37 +0100" MODIFIED_BY="Ruth Brassington">
<BACKGROUND MODIFIED="2016-10-03 15:19:59 +0100" MODIFIED_BY="Ruth Brassington">
<P>Guillain-Barré syndrome (GBS) is an acute paralysing illness usually due to inflammation of the peripheral nerves and nerve roots. It causes tingling and numbness in the limbs and rapidly progressive weakness so that people lose the ability to walk. It may affect the face and swallowing muscles and 25% of people with GBS become so weak that they require artificial ventilation. About 5% of people with GBS die in the acute stages and 10% are left with permanent severe disability. It affects 1 to 2 per 100,000 of the population throughout the world and is more common in the elderly than the young. The cause of GBS is not definitely known. It is probably an autoimmune disease in which the autoimmune response, often triggered by an infection, is directed against antigens in the nerve. This leads to inflammation and nerve damage. Two principal subtypes of GBS are now recognised, acute inflammatory demyelinating polyradiculoneuropathy and acute motor axonal neuropathy. Acute inflammatory demyelinating polyradiculoneuropathy accounts for most of the disease in Europe and North America and acute motor axonal neuropathy is more common in Central America and South East China. In acute inflammatory demyelinating polyradiculoneuropathy the attack focusses on the myelin sheath but the precise target is unknown. In acute motor axonal neuropathy there is good evidence that the target is one or more ganglioside (a form of glycolipid) molecules on the outer membrane of the axon, the central conducting core of the nerve fibre (<LINK REF="REF-Willison-2016" TYPE="REFERENCE">Willison 2016</LINK>). The trials conducted so far have not distinguished the different subtypes of GBS. We do not know whether the subtype influences the prognosis from GBS but older age, preceding history of diarrhoea, and greater disease severity all adversely affect prognosis (<LINK REF="REF-Walgaard-2011" TYPE="REFERENCE">Walgaard 2011</LINK>).</P>
<P>Two treatments designed to reduce the presumptive autoimmune response do work in GBS. One Cochrane review concluded from randomised controlled trials (RCTs) that replacing the blood plasma by plasma exchange is beneficial (<LINK REF="REF-Rapha_x00eb_l-2012" TYPE="REFERENCE">Raphaël 2012</LINK>). Another review concluded that intravenous immunoglobulin (IVIg) is just as helpful (<LINK REF="REF-Hughes-2014" TYPE="REFERENCE">Hughes 2014</LINK>). Theoretically, corticosteroids would be expected to reduce inflammation and so lessen nerve damage in inflammatory neuropathy. Corticosteroids have been shown to hasten recovery in a rat model of GBS, experimental autoimmune neuritis, but only when used in large doses (<LINK REF="REF-Hughes-1981" TYPE="REFERENCE">Hughes 1981</LINK>; <LINK REF="REF-King-1985" TYPE="REFERENCE">King 1985</LINK>; <LINK REF="REF-Watts-1989" TYPE="REFERENCE">Watts 1989</LINK>). However, corticosteroids introduce risks, including that of increased susceptibility to infection (<LINK REF="REF-Bromberg-2004" TYPE="REFERENCE">Bromberg 2004</LINK>). Consequently the risk-benefit ratio of corticosteroid administration in GBS requires careful study.</P>
<P>Corticosteroid treatment has been used in GBS in individual case reports from the early 1950s onwards. Some authors reported apparently favourable responses from small series or comparative but not controlled studies. No consensus about the efficacy of steroid treatment emerged from this work (see <LINK REF="REF-Hughes-1990" TYPE="REFERENCE">Hughes 1990</LINK> and <LINK REF="REF-Ropper-1991" TYPE="REFERENCE">Ropper 1991</LINK> for reviews). A retrospective cohort study compared 50 participants treated with prednisolone 1 mg/kg daily, or equivalent doses of dexamethasone, with 47 participants treated without corticosteroids (<LINK REF="REF-Peter-1996" TYPE="REFERENCE">Peter 1996</LINK>). The baseline characteristics of the two groups appeared similar. There was no significant difference between the groups in mortality, intensive care unit stay, or improvement in disability by the time of hospital discharge. Complications were more common in the corticosteroid group. However, a comparison of one series of corticosteroid-treated participants with historical controls suggested a beneficial effect from corticosteroids when given in combination with IVIg (<LINK REF="REF-Dutch-GBS-Group-1994" TYPE="REFERENCE">Dutch GBS Group 1994</LINK>). In that study, 25 participants were treated with intravenous methylprednisolone 500 mg daily for five days in addition to IVIg 0.4 g/kg daily for five days. They were compared with a historical comparative group of 74 participants treated without steroids but also without IVIg (<LINK REF="REF-Dutch-GBS-Group-1994" TYPE="REFERENCE">Dutch GBS Group 1994</LINK>). After four weeks, 19 of the 25 methylprednisolone-treated participants (76%) improved by one or more disability grades on a seven-point scale, compared with only 39 of 74 (53%) participants treated in a previously controlled trial with IVIg but not corticosteroids (P = 0.04).</P>
<P>The first version of this review, published in 1999, included six RCTs and a total of 382 participants. We updated the review in 2007 to include a new trial with 225 participants (<LINK REF="STD-van-Koningsveld-2004" TYPE="STUDY">van Koningsveld 2004</LINK>), and a newly discovered trial with 20 participants (<LINK REF="STD-Garcia-1985" TYPE="STUDY">Garcia 1985</LINK>). We updated the review in June 2009, November 2011, and January 2016 but found no more new trials.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-10-03 15:20:01 +0100" MODIFIED_BY="Ruth Brassington">
<P>To examine the ability of corticosteroids to hasten recovery and reduce the long-term morbidity from Guillain-Barré syndrome.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-10-03 15:20:47 +0100" MODIFIED_BY="Ruth Brassington">
<SELECTION_CRITERIA MODIFIED="2016-10-03 15:20:09 +0100" MODIFIED_BY="Ruth Brassington">
<CRIT_STUDIES MODIFIED="2016-10-03 15:20:02 +0100" MODIFIED_BY="Ruth Brassington">
<P>We included all randomised controlled trials (RCTs) or quasi-RCTs (e.g. alternate allocation) of corticosteroid or adrenocorticotrophic hormone (ACTH) treatment for Guillain-Barré syndrome (GBS). The type of additional therapy given, if any, did not affect inclusion in this review.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-10-03 15:20:02 +0100" MODIFIED_BY="Ruth Brassington">
<P>We included children and adults with GBS of all degrees of severity. We defined GBS according to internationally accepted diagnostic criteria as acute polyradiculoneuropathy causing progressive weakness of two or more limbs, an onset phase not more than four weeks, reduced or absent tendon reflexes, and lacking alternative causes (<LINK REF="REF-Asbury-1990" TYPE="REFERENCE">Asbury 1990</LINK>). We included studies that did not conform exactly to these criteria provided that the authors regarded GBS or one of its synonyms, such as acute idiopathic neuropathy or acute inflammatory demyelinating polyradiculoneuropathy, as the preferred diagnosis. We noted any departure from the internationally accepted diagnostic criteria.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-10-03 15:20:03 +0100" MODIFIED_BY="Ruth Brassington">
<P>We included treatment with any form of corticosteroid or adrenocorticotrophic hormone (ACTH).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-10-03 15:20:09 +0100" MODIFIED_BY="Ruth Brassington">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-10-03 15:20:08 +0100" MODIFIED_BY="Ruth Brassington">
<OL>
<LI>Improvement in disability grade four weeks after randomisation.</LI>
</OL>
<P>We accepted the disability scale used by the authors of each trial provided that it was closely similar to that described in one of the first trials (<LINK REF="STD-Hughes-1978" TYPE="STUDY">Hughes 1978</LINK>), as follows.</P>
<P>0. Healthy.<BR/>1. Minor symptoms or signs of neuropathy but capable of manual work.<BR/>2. Able to walk without support of a stick but incapable of manual work.<BR/>3. Able to walk with a stick, appliance, or support.<BR/>4. Confined to bed or chair bound.<BR/>5. Requiring assisted ventilation.<BR/>6. Dead.</P>
<P>In the calculation of grade changes, we followed the convention that participants who died were assigned a disability score of six and retained in the analysis with this score at subsequent follow-up intervals.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-10-03 15:20:09 +0100" MODIFIED_BY="Ruth Brassington">
<OL>
<LI>Improvement by one or more disability grades on the scale described above, four weeks after randomisation. This measure had not been included in the first version of this review but was used in reviews of plasma exchange and intravenous immunoglobulin (IVIg) and has been added to this review for consistency and comparison.</LI>
<LI>Time from randomisation until recovery of unaided walking.</LI>
<LI>Time from randomisation until discontinuation of ventilation (for ventilated participants).</LI>
<LI>Death.</LI>
<LI>Death or disability (inability to walk without aid after 12 months).</LI>
<LI>Improvement in disability grade after six months.</LI>
<LI>Improvement in disability grade after 12 months.</LI>
<LI>Relapse (defined as a period of worsening lasting at least seven days that followed a period of improvement lasting at least seven days) during the first year after randomisation.</LI>
<LI>Occurrence of the following adverse events that are attributable to corticosteroids during or within one week after stopping treatment:</LI>
<OL>
<LI>development of new infection treated with antibiotics;</LI>
<LI>gastrointestinal haemorrhage;</LI>
<LI>development of diabetes mellitus requiring insulin;</LI>
<LI>development of hypertension requiring drug treatment.</LI>
</OL>
</OL>
<P>The most informative outcomes, selected for inclusion in the 'Summary of findings' table in this update, were the following.</P>
<OL>
<LI>Improvement by one or more disability grades four weeks after randomisation (primary outcome).</LI>
<LI>Death or disability (inability to walk without aid after 12 months).</LI>
<LI>Development of diabetes mellitus requiring insulin.</LI>
<LI>Development of hypertension requiring drug treatment.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-10-03 15:20:26 +0100" MODIFIED_BY="Ruth Brassington">
<P>On 12 January 2016 we searched the Cochrane Neuromuscular Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL in the Cochrane Register of Studies Online), MEDLINE (January 1966 to December 2016), and Embase (January 1980 to January 2016). We also searched ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>) and the World Health Organization (WHO) international Clinical Trials Registry Platform (<A HREF="http://apps.who.int/trialsearch/">apps.who.int/trialsearch/</A>) on 27 January 2016.<BR/>
</P>
<ELECTRONIC_SEARCHES MODIFIED="2016-09-20 14:39:56 +0100" MODIFIED_BY="Ruth Brassington" NOTES="&lt;p&gt;I have searched &lt;a href=&quot;http://apps.who.int/trialsearch/&quot; protected=&quot;true&quot;&gt;http://apps.who.int/trialsearch/&lt;/a&gt; (WHO international Clinical trials Registry) on 27.1.16. 33 refs to 29 trials. None relevant to this review. Richard&lt;/p&gt;" NOTES_MODIFIED="2016-09-20 14:39:56 +0100" NOTES_MODIFIED_BY="Ruth Brassington">
<P>The detailed search strategies are in the appendices: Cochrane Neuromuscular Specialised Register <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>; CENTRAL <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>; MEDLINE <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>, Embase <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>), and trials registries <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-10-03 15:20:26 +0100" MODIFIED_BY="Ruth Brassington">
<P>We checked the bibliographies in reports of the RCTs and contacted the trial authors and other experts in the field to identify additional published or unpublished data.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-10-03 15:20:47 +0100" MODIFIED_BY="Ruth Brassington">
<STUDY_SELECTION MODIFIED="2016-10-03 15:20:27 +0100" MODIFIED_BY="Ruth Brassington">
<P>Two review authors independently checked titles and abstracts identified from the register. Two review authors obtained the full text of all potentially relevant studies for independent assessment. The review authors decided independently which trials fitted the inclusion criteria and graded their risk of bias. The review authors resolved disagreements about inclusion criteria by discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-10-03 15:20:29 +0100" MODIFIED_BY="Ruth Brassington">
<P>Two review authors independently performed data extraction. We obtained some missing data from trial authors.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-10-03 15:20:31 +0100" MODIFIED_BY="Ruth Brassington">
<P>The assessment of risk of bias in the trials included random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, incomplete outcome data, selective outcome reporting, and other sources of bias (e.g. differences in adherence to treatment or baseline differences not explained under other domains). We assessed blinding and incomplete outcome data separately for death and outcomes other than death.</P>
<P>We graded the 'Risk of bias' items as having high, low, or unclear risk. When agreement between review authors was poor, we reassessed the studies and reached agreement by consensus.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-10-03 15:20:41 +0100" MODIFIED_BY="Ruth Brassington">
<P>We calculated a treatment effect across trials using the Cochrane statistical package, Review Manager 5 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). We expressed results as risk ratios with 95% confidence intervals (CIs) and risk differences with 95% CIs for dichotomous outcomes and mean differences and 95% CIs for continuous outcomes. We combined the effects of two trials using an inverse variance meta-analysis generating log odds ratios (log OR), which could be converted to an adjusted OR in the results.</P>
</EFFECT_MEASURES>
<DATA_SYNTHESIS MODIFIED="2016-08-08 15:24:40 +0100" MODIFIED_BY="KLJ ">
<P>We used a fixed-effect model and tested for heterogeneity. Where we found genuine heterogeneity, not due to a few extreme studies, we substituted a random-effects model. We analysed all the primary and secondary outcomes under consideration whenever the data allowed.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-10-03 15:20:47 +0100" MODIFIED_BY="Ruth Brassington">
<P>We planned to examine subgroups that had been defined in advance because of their prognostic importance as identified in previous prospective studies and trials. We defined the subgroups according to the status of the participants at randomisation as follows.</P>
<OL>
<LI>Younger and older (children and adults up to 49 years of age; adults aged 50 years or more).</LI>
<LI>More severely affected (requiring ventilation) or less severely affected (not requiring ventilation).</LI>
<LI>Having or not having documented relevant sensory deficit on routine neurological examination (symptoms alone were to be ignored).</LI>
<LI>Having or not having a history of diarrhoea (gastroenteritis) within the six weeks before the onset of neuropathic symptoms.</LI>
<LI>Time from onset of neuropathy to start of treatment (seven days or less after onset; more than seven, up to 14 days after onset; and more than 14 days after onset).</LI>
</OL>
<P>Before the outcome of the <LINK REF="STD-van-Koningsveld-2004" TYPE="STUDY">van Koningsveld 2004</LINK> trial was known, we decided to examine separately the effects of intravenous and oral regimens.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-08-08 15:24:53 +0100" MODIFIED_BY="KLJ ">
<P>We undertook sensitivity analyses taking into account the risk of bias of the studies, specifically the effect of removing trials without adequate allocation concealment.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-10-03 15:27:37 +0100" MODIFIED_BY="Ruth Brassington">
<STUDY_DESCRIPTION MODIFIED="2016-10-03 15:21:23 +0100" MODIFIED_BY="Ruth Brassington">
<SEARCH_RESULTS MODIFIED="2016-10-03 15:21:06 +0100" MODIFIED_BY="Ruth Brassington">
<P>The original search of the Cochrane Neuromuscular Specialised Register revealed eight references that might have been randomised controlled trials (RCTs) (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). We excluded three studies: <LINK REF="STD-Levchenko-1989" TYPE="STUDY">Levchenko 1989</LINK> was not a randomised study, <LINK REF="STD-Mendell-1985" TYPE="STUDY">Mendell 1985</LINK> provided both plasma exchange and corticosteroids to the experimental group but neither to the control group, and <LINK REF="STD-Zagar-1995" TYPE="STUDY">Zagar 1995</LINK> was a review. Advertising for more trials among colleagues identified a further possible trial (<LINK REF="STD-Haass-1988" TYPE="STUDY">Haass 1988</LINK>), but this was an observational study with no control group (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table). Our search of Embase revealed six references that might have represented RCTs, including three that had not been detected by the other searches. We included <LINK REF="STD-Bansal-1986" TYPE="STUDY">Bansal 1986</LINK>, which was a quasi-RCT, and excluded two other studies, which were observational (<LINK REF="STD-El-Zunni-1997" TYPE="STUDY">El Zunni 1997</LINK>; <LINK REF="STD-Naylor-1986" TYPE="STUDY">Naylor 1986</LINK>). We identified another RCT by personal contact with the author (<LINK REF="STD-Foyaca-2003" TYPE="STUDY">Foyaca 2003</LINK>). We excluded this trial because it did not meet our requirement for adequate diagnostic criteria as participants were included who had pure sensory deficit, facial diplegia with paraesthesiae, or hyper-reflexia. In addition, the trial did not meet our criteria for adequate definition of a single primary outcome, and allocation concealment was unclear. When we repeated the searches in January 2016, the total number of papers retrieved from the Cochrane Neuromuscular Specialised Register was 60 (36 new), CENTRAL 76 (45 new), MEDLINE 606 (90 new), and Embase 349 (77 new). After deduplication, there were 212 new records but none were RCTs suitable for inclusion. There were no other or ongoing trials in the clinical trials registries.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-10-03 15:21:23 +0100" MODIFIED_BY="Ruth Brassington">
<P>Eight trials, including 653 participants, fulfilled the selection criteria (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). All the trials used internationally accepted diagnostic criteria (<LINK REF="REF-Asbury-1990" TYPE="REFERENCE">Asbury 1990</LINK>) or closely similar explicit criteria.</P>
<P>Only six trials with 587 participants provided data for our primary outcome measure. The first trial compared intramuscular ACTH daily for 10 days with placebo (<LINK REF="STD-Swick-1976" TYPE="STUDY">Swick 1976</LINK>). Four trials with between 14 and 46 participants compared oral prednisolone with placebo (<LINK REF="STD-Shukla-1988" TYPE="STUDY">Shukla 1988</LINK>; <LINK REF="STD-Singh-1996" TYPE="STUDY">Singh 1996</LINK>), or supportive treatment without steroids and no placebo (<LINK REF="STD-Bansal-1986" TYPE="STUDY">Bansal 1986</LINK>; <LINK REF="STD-Hughes-1978" TYPE="STUDY">Hughes 1978</LINK>). The oral regimens varied but all consisted of the equivalent of prednisolone 40 mg daily for at least two weeks. A trial with alternate allocation included 10 participants treated with methylprednisolone 1500 mg daily for five days and 10 participants who received supportive care (<LINK REF="STD-Garcia-1985" TYPE="STUDY">Garcia 1985</LINK>). A trial with 242 participants compared intravenous methylprednisolone 500 mg daily for five days with an identical placebo saline solution (<LINK REF="STD-GBS-Steroid-1993" TYPE="STUDY">GBS Steroid 1993</LINK>). This trial did not show a significant difference in any outcome between the corticosteroid- and placebo-treated groups. One trial with 225 participants differed from the others in that all participants received IVIg 0.4 g/kg daily for five days in accordance with current practice and were randomly allocated to receive intravenous methylprednisolone 500 mg daily for five days, or an identical saline placebo (<LINK REF="STD-van-Koningsveld-2004" TYPE="STUDY">van Koningsveld 2004</LINK>). In this trial, the authors reported a one disability grade improvement after four weeks in 63 of 113 (56%) of control- and 76 of 112 (68%) methylprednisolone-treated participants (risk ratio (RR) 1.2, 95% confidence interval (CI) 1.0 to 1.5, P = 0.06), a difference which was not quite significant. After adjustment for age and severity of disability at randomisation, the treatment effect just achieved significance (RR 1.3, 95% CI 1.0 to 1.5, P = 0.03). When the authors also adjusted for other prognostic factors not defined in the protocol (number of days between onset of weakness and randomisation, preceding infection with cytomegalovirus, and the amplitude of compound muscle action potential (CMAP)) that were unbalanced between the treatment groups, the odds ratio (OR) favoured the primary outcome (OR 2.96, 95% CI 1.26 to 6.94, P = 0.01). Other outcomes, including the proportion of participants requiring ventilation, becoming able to walk unaided, and improving one or more disability grades during the first year, did not differ significantly between the groups.</P>
</INCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-10-03 15:21:54 +0100" MODIFIED_BY="Ruth Brassington">
<P>
<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> gives the risk of bias for each trial. Allocation concealment was adequate in four trials in which participants were randomly assigned to receive corticosteroids or ACTH or an identical-appearing placebo (<LINK REF="STD-GBS-Steroid-1993" TYPE="STUDY">GBS Steroid 1993</LINK>; <LINK REF="STD-Hughes-1978" TYPE="STUDY">Hughes 1978</LINK>; <LINK REF="STD-Swick-1976" TYPE="STUDY">Swick 1976</LINK>; <LINK REF="STD-van-Koningsveld-2004" TYPE="STUDY">van Koningsveld 2004</LINK>). One trial assigned participants to oral prednisolone or no corticosteroid treatment according to a central register of random numbers that was only revealed at the time of randomisation (<LINK REF="STD-Hughes-1978" TYPE="STUDY">Hughes 1978</LINK>). In this trial, the treatment allocation concealment was also considered adequate. In <LINK REF="STD-Shukla-1988" TYPE="STUDY">Shukla 1988</LINK>, participants were randomly allocated to corticosteroids or placebo but it was not clear whether allocation was concealed. In three trials, participants were alternately assigned to corticosteroid or supportive care and we considered the randomisation concealment inadequate (<LINK REF="STD-Bansal-1986" TYPE="STUDY">Bansal 1986</LINK>; <LINK REF="STD-Garcia-1985" TYPE="STUDY">Garcia 1985</LINK>; <LINK REF="STD-Singh-1996" TYPE="STUDY">Singh 1996</LINK>).</P>
<P>Participant blinding was intended in five trials but not in three (<LINK REF="STD-Bansal-1986" TYPE="STUDY">Bansal 1986</LINK>; <LINK REF="STD-Garcia-1985" TYPE="STUDY">Garcia 1985</LINK>; <LINK REF="STD-Hughes-1978" TYPE="STUDY">Hughes 1978</LINK>). None of the trials recorded effectiveness of blinding. One trial did not blind participants but did blind the observers (<LINK REF="STD-Hughes-1978" TYPE="STUDY">Hughes 1978</LINK>). All trials considered baseline clinical features. In three trials the baseline clinical features were similar between intervention groups. In three trials, baseline differences were present: in the trial of <LINK REF="STD-Swick-1976" TYPE="STUDY">Swick 1976</LINK>, the time to nadir was shorter in the corticosteroid group, in <LINK REF="STD-Bansal-1986" TYPE="STUDY">Bansal 1986</LINK>, the corticosteroid-treated participants were 10 years older, and in <LINK REF="STD-Singh-1996" TYPE="STUDY">Singh 1996</LINK>, corticosteroid-treated participants were older and more disabled than the control groups. Doubt also arose concerning this question in <LINK REF="STD-GBS-Steroid-1993" TYPE="STUDY">GBS Steroid 1993</LINK>, in which there was an imbalance not at baseline but in the subsequent treatment of the two groups, since more of the participants in the placebo group received plasma exchange than participants in the corticosteroid group (see <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK>). In one trial, there was a slight imbalance at randomisation in the number of days between onset and randomisation (four days or less versus more than four days), amplitude of the CMAP, and presence or absence of preceding cytomegalovirus infection, all factors reported to affect prognosis (<LINK REF="STD-van-Koningsveld-2004" TYPE="STUDY">van Koningsveld 2004</LINK>). Follow-up continued for a year in three trials (<LINK REF="STD-GBS-Steroid-1993" TYPE="STUDY">GBS Steroid 1993</LINK>; <LINK REF="STD-Hughes-1978" TYPE="STUDY">Hughes 1978</LINK>; <LINK REF="STD-van-Koningsveld-2004" TYPE="STUDY">van Koningsveld 2004</LINK>). The commonest problem was that the small trials did not state the primary outcome in the methods section of the paper. The two large trials did state the primary outcome (<LINK REF="STD-GBS-Steroid-1993" TYPE="STUDY">GBS Steroid 1993</LINK>; <LINK REF="STD-van-Koningsveld-2004" TYPE="STUDY">van Koningsveld 2004</LINK>). There was no evidence otherwise of selective reporting in any of the trials.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-10-03 15:27:37 +0100" MODIFIED_BY="Ruth Brassington">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcome measure</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Change in disability grade four weeks after randomisation</HEADING>
<P>Information for this outcome was available for six trials with 587 participants, of whom 297 received corticosteroids and 290 did not. In the analysis of all these trials there was no significant difference between the groups: the mean difference (MD) was 0.36 of a grade less improvement in the corticosteroid-treated participants. The 95% CI ranged from 0.88 of a grade less improvement to 0.16 of a grade more improvement (see 
<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> and <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). There was significant heterogeneity in this analysis so we used a random-effects model for this computation. Inspection of the forest plot suggested more benefit from the intravenous regimens so that we undertook separate analyses of the trials that used oral and intravenous regimens. In the four small trials that used oral corticosteroids, there were 120 participants and there was significantly less improvement in corticosteroid-treated participants than in controls (MD 0.82, 95% CI 0.17 to 1.47) (<LINK REF="STD-Bansal-1986" TYPE="STUDY">Bansal 1986</LINK>; <LINK REF="STD-Hughes-1978" TYPE="STUDY">Hughes 1978</LINK>; <LINK REF="STD-Shukla-1988" TYPE="STUDY">Shukla 1988</LINK>; <LINK REF="STD-Singh-1996" TYPE="STUDY">Singh 1996</LINK>). In the two large trials with 467 participants that used intravenous methylprednisolone, the MD was 0.17 of a grade more improvement in participants treated with intravenous methylprednisolone (<LINK REF="STD-GBS-Steroid-1993" TYPE="STUDY">GBS Steroid 1993</LINK>; <LINK REF="STD-van-Koningsveld-2004" TYPE="STUDY">van Koningsveld 2004</LINK>). The 95% CIs ranged from 0.06 of a grade less improvement to 0.39 of a grade more improvement.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Improvement by one or more disability grades after four weeks</HEADING>
<P>Information for this outcome was available for five trials with 567 participants. The information for this outcome was not available for Bansal 1986. The RR of improving by one or more grades from baseline was 1.08 (95% CI 0.93 to 1.24) more in the corticosteroid-treated than the control participants (see <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). In other words, the absolute rate of participants improving one grade was 8% more with corticosteroids, with 95% CIs ranging from 7% less to 24% more.</P>
<P>There was no significant heterogeneity in this analysis. In the three small oral corticosteroid trials there were 100 participants and the relative rate of improvement was less in the corticosteroid-treated participants but the difference was not significant (MD 0.80, 95% CI 0.55 to 1.16). When we confined this analysis to the two large trials that used intravenous methylprednisolone, the RR of improvement did not achieve significance, being 1.14 (95% CI 0.97 to 1.34) greater in the intravenous methylprednisolone-treated participants than the control group (see 
<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK> and <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). In other words, the absolute rate of participants improving one grade was 14% more with corticosteroids, with 95% CIs ranging from 3% less to 34% more.</P>
<P>We checked that there were no interactions between treatment, age, or initial disability for this outcome in the two large trials that provided data. We tested the effect of age (less than 50 years and 50 years or more) and initial disability with an inverse variance meta-analysis combining the results of the <LINK REF="STD-GBS-Steroid-1993" TYPE="STUDY">GBS Steroid 1993</LINK> and <LINK REF="STD-van-Koningsveld-2004" TYPE="STUDY">van Koningsveld 2004</LINK> trials. The result gave an adjusted log OR of 0.34 (95% CI -0.05 to 0.73) (see <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). This is equivalent to an adjusted OR of 1.41 (95% CI 0.95 to 2.07, P = 0.08), which was in favour of corticosteroids but not significant. Assuming that in the controls the probability of recovering one or more grades is the average of those observed in the two studies, that is 53.2%, then these adjusted log OR results are equivalent to an RR of improvement of 1.16 (95% CI 0.98 to 1.32, P = 0.08) more with corticosteroids than with placebo, again not significant at the 5% level. This is very little different to the unadjusted pooled RR of 1.14 (95% CI 0.97 to 1.34) (see <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Time from randomisation until recovery of unaided walking</HEADING>
<P>We derived the outcome of time from randomisation until recovery of unaided walking for this review from the original data of <LINK REF="STD-Hughes-1978" TYPE="STUDY">Hughes 1978</LINK>, in which the median time to walk unaided was 29 days (95% CI 16.4 to 73.8) in the group treated with oral prednisolone and 34 days (95% CI 18.8 to 181.4) in the control group. The difference between the groups, 5 days (95% CI -95 to 105) less in the corticosteroid group, was not significant (P = 0.37). The largest study also published data on this outcome (<LINK REF="STD-GBS-Steroid-1993" TYPE="STUDY">GBS Steroid 1993</LINK>), in which the median time to walk unaided was 38 days in the group treated with steroids compared to 50 days in the placebo group. The difference between the groups, 12 days (95% CI -21.3 to 45.3) less in the corticosteroid group, was not significant. In the most recent trial (<LINK REF="STD-van-Koningsveld-2004" TYPE="STUDY">van Koningsveld 2004</LINK>), the median time to walk unaided in the corticosteroid-treated participants was 28 days (interquartile ratio (IQR) of the individual values 14 to 154 days), approximately equivalent to 95% CI of the median of 4 to 52 days) and 56 days (IQR 14 to 154 days, approximately equivalent to 95% CI of 32 to 80 days) in the placebo-treated participants. The difference between the groups was 28 days less in the corticosteroid-treated participants (95% CI -6.0 to 62.0), but this difference was not significant.</P>
<P>Only one other trial reported similar outcome measures. The study of ACTH included median time to complete recovery as an outcome measure, which was 4 months (95% CI 2 to 6) in the participants treated with ACTH and 10 months (95% CI 4.5 to 12) in the participants treated with placebo (<LINK REF="STD-Swick-1976" TYPE="STUDY">Swick 1976</LINK>). It is difficult to compute the significance of this observation since there were only nine participants in the corticosteroid group and seven in the placebo group; one participant in the treatment group died and was omitted from the data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Time from randomisation until discontinuation of ventilation (for ventilated participants)</HEADING>
<P>In <LINK REF="STD-GBS-Steroid-1993" TYPE="STUDY">GBS Steroid 1993</LINK>, the median time from randomisation to discontinuation of ventilation was 18 days in the group treated with intravenous methylprednisolone and 27 days in the placebo group (difference 12 days shorter with corticosteroids, 95% CI 21.3 longer to 45.3 days shorter). In contradiction to this, in <LINK REF="STD-van-Koningsveld-2004" TYPE="STUDY">van Koningsveld 2004</LINK>, the median time from randomisation to discontinuation of ventilation was longer at 30 days (95% CI 16.6 to 43.4) in the 24 participants treated with intravenous methylprednisolone and IVIg, compared with 26 days (95% CI 15.3 to 36.7) in the 26 control participants treated with placebo and IVIg.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Death</HEADING>
<P>Mortality data were available from seven trials with 605 participants in total. Twenty of 308 (6.5%) participants treated with corticosteroids died during the trial follow-up compared with 14 of 297 (4.7%) participants treated without corticosteroids, giving an insignificant difference with an RR of 1.28 (95% CI 0.67 to 2.47) more deaths in the corticosteroid-treated participants (see <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). This analysis included all recorded deaths regardless of the length of follow-up and even if the trial authors had excluded the case because they considered that the death was due to an unrelated cause. We included a participant who was randomised to ACTH in <LINK REF="STD-Swick-1976" TYPE="STUDY">Swick 1976</LINK>, left hospital against advice, and died at home. We also included a participant randomised to no steroid treatment in another trial, who died of suicide during convalescence (<LINK REF="STD-Hughes-1978" TYPE="STUDY">Hughes 1978</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Death or disability (inability to walk without aid) after 12 months</HEADING>
<P>In the three trials in which this outcome was available (<LINK REF="STD-GBS-Steroid-1993" TYPE="STUDY">GBS Steroid 1993</LINK>; <LINK REF="STD-Hughes-1978" TYPE="STUDY">Hughes 1978</LINK>; <LINK REF="STD-van-Koningsveld-2004" TYPE="STUDY">van Koningsveld 2004</LINK>), 35 of 252 (13.9%) participants treated with oral prednisolone or intravenous methylprednisolone were dead or disabled (needing aid to walk) after one year, compared with 22 of 239 (9.2%) control participants. The RR of this combined outcome was not significantly different, being 1.51 (95% CI 0.91 to 2.50) more in the corticosteroid than the placebo-treated participants (see 
<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> and <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Improvement in disability grade after six months</HEADING>
<P>We obtained data for this outcome from the two largest trials, which had 455 participants (<LINK REF="STD-GBS-Steroid-1993" TYPE="STUDY">GBS Steroid 1993</LINK>; <LINK REF="STD-van-Koningsveld-2004" TYPE="STUDY">van Koningsveld 2004</LINK>). No significant difference was present between the corticosteroid-treated and the placebo-treated participants, MD 0.10 (95% CI -0.16 to 0.36) of a grade more improvement in the corticosteroid-treated participants (see 
<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). The mean disability grades of the corticosteroid and control groups were not significantly different after six months in one other trial (<LINK REF="STD-Singh-1996" TYPE="STUDY">Singh 1996</LINK>), but the trial authors did not provide the standard deviations, so the meta-analysis did not include this study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7. Improvement in disability grade after 12 months</HEADING>
<P>This outcome was available for three trials with 471 participants in total (<LINK REF="STD-GBS-Steroid-1993" TYPE="STUDY">GBS Steroid 1993</LINK>; <LINK REF="STD-Hughes-1978" TYPE="STUDY">Hughes 1978</LINK>; <LINK REF="STD-van-Koningsveld-2004" TYPE="STUDY">van Koningsveld 2004</LINK>), showing almost no difference, MD of -0.03 (95% CI -0.29 to 0.23) less improvement in the corticosteroid group (see 
<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>) (<LINK REF="STD-GBS-Steroid-1993" TYPE="STUDY">GBS Steroid 1993</LINK>; <LINK REF="STD-Hughes-1978" TYPE="STUDY">Hughes 1978</LINK>; <LINK REF="STD-van-Koningsveld-2004" TYPE="STUDY">van Koningsveld 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">8. Relapse (defined as a period of worsening lasting at least seven days that followed a period of improvement lasting at least seven days) during the first year after randomisation</HEADING>
<P>Three trials reported relapses during the first year after treatment (<LINK REF="STD-GBS-Steroid-1993" TYPE="STUDY">GBS Steroid 1993</LINK>; <LINK REF="STD-Hughes-1978" TYPE="STUDY">Hughes 1978</LINK>; <LINK REF="STD-van-Koningsveld-2004" TYPE="STUDY">van Koningsveld 2004</LINK>). Eighteen of 251 participants treated with corticosteroids relapsed compared with 15 of 239 control participants, an insignificant difference, with an RR of 1.14 (95% CI 0.59 to 2.18) (see <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">9. Occurrence of specific adverse events that are attributable to corticosteroids during or within one week after stopping treatment</HEADING>
<P>
<LINK REF="STD-Shukla-1988" TYPE="STUDY">Shukla 1988</LINK> reported one participant out of eight treated with prednisolone who developed a perforated peptic ulcer and another who developed psychosis, but did not mention any such complications in eight placebo-treated participants. Five trials did not report side effects or adverse events (<LINK REF="STD-Hughes-1978" TYPE="STUDY">Hughes 1978</LINK>; <LINK REF="STD-Singh-1996" TYPE="STUDY">Singh 1996</LINK>; <LINK REF="STD-Swick-1976" TYPE="STUDY">Swick 1976</LINK>; <LINK REF="STD-van-Koningsveld-2004" TYPE="STUDY">van Koningsveld 2004</LINK>). Two trials that used intravenous methylprednisolone provided information concerning the adverse events that had been preselected for this review and have been illustrated in the analyses. This is summarised as follows.</P>
<SUBSECTION>
<HEADING LEVEL="5">a. Development of new infection treated with antibiotics</HEADING>
<P>In the first large trial, 25 of 124 (20.2%) participants treated with intravenous methylprednisolone had infection or septicaemia during the first four weeks of treatment; the proportion in the placebo group was similar, 25 of 118 (21.2%) (<LINK REF="STD-GBS-Steroid-1993" TYPE="STUDY">GBS Steroid 1993</LINK>). In the second large trial, fewer participants treated with intravenous methylprednisolone (20/112, 18%) had urinary tract infections than in the placebo group (35/113, 31%, P = 0.01), the opposite of the result that might have been expected (<LINK REF="STD-van-Koningsveld-2004" TYPE="STUDY">van Koningsveld 2004</LINK>). It is doubtful whether these two data sets should be analysed together but when this was done the RR of infection was not significantly different (RR 0.74, 95% CI 0.52 to 1.04) (see <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">b. Gastrointestinal haemorrhage</HEADING>
<P>The first large trial reported haemorrhage in 3 of 124 (2.4%) corticosteroid-treated and 3 of 118 (2.5%) placebo-treated participants but did not report the site of haemorrhage (<LINK REF="STD-GBS-Steroid-1993" TYPE="STUDY">GBS Steroid 1993</LINK>). In the second large trial, gastrointestinal haemorrhage occurred in 3 of 112 (2.6%) corticosteroid-treated and 2 of 113 (1.8%) placebo-treated participants (<LINK REF="STD-van-Koningsveld-2004" TYPE="STUDY">van Koningsveld 2004</LINK>). Again it is doubtful whether these two data sets should be analysed together but when this was done the RR of infection was not significant (RR 1.17, 95% CI 0.36 to 3.78) (see <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">c. Development of diabetes mellitus requiring insulin</HEADING>
<P>Our protocol included comparison of the proportions of participants who developed diabetes mellitus requiring the use of insulin. Neither trial stipulated this precise outcome, but measured related outcomes. In the first large trial, investigators reported diabetes mellitus in 5 of 124 (4.0%) corticosteroid-treated and 5 of 118 (4.2%) placebo-treated participants (<LINK REF="STD-GBS-Steroid-1993" TYPE="STUDY">GBS Steroid 1993</LINK>). They did not state their definition of diabetes. In <LINK REF="STD-van-Koningsveld-2004" TYPE="STUDY">van Koningsveld 2004</LINK>, a plasma glucose greater than 10 mmol/L occurred in 24 of 112 (21%) corticosteroid-treated and 8 of 113 (7%) placebo-treated participants (P = 0.01). When these results were combined, the RR of diabetes was significantly greater with corticosteroid treatment (RR 2.21, 1.19 to 4.12, P = 0.01) (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> and <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">d. Development of hypertension requiring drug treatment</HEADING>
<P>In both the large trials, hypertension was significantly less frequent in the steroid-treated than the control group. When we combined the results, there were highly significantly fewer participants who developed hypertension in the intravenous methylprednisolone group, 4 of 236 (1.7%) than in the placebo group, 27 of 231 (7.4%) (RR 0.15, 95% CI 0.05 to 0.41, P = 0.0003) (see 
<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> and <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analysis</HEADING>
<P>In the absence of a significant main effect of corticosteroids on the primary outcome measure, it is questionable whether meta-analysis of the effect on subgroups is appropriate. In one small trial of oral prednisolone, the improvement of six participants randomised to corticosteroids within the first week after onset was non-significantly worse four weeks after randomisation and significantly worse three months after randomisation compared with 10 control participants randomised within the same period (<LINK REF="STD-Hughes-1978" TYPE="STUDY">Hughes 1978</LINK>). Other information for the analyses of the subgroups we selected was not available in the published reports. However, published analyses in two of the large trials addressed this problem. In the published report of <LINK REF="STD-GBS-Steroid-1993" TYPE="STUDY">GBS Steroid 1993</LINK>, a regression analysis found no interaction between age, severity at onset, or delay from onset until randomisation (within the maximum permitted period, which was 14 days) and the effect of treatment. Similarly, in <LINK REF="STD-van-Koningsveld-2004" TYPE="STUDY">van Koningsveld 2004</LINK>, no treatment interactions with age (less than 50 years or 50 years and more), disability score, duration of weakness (four days or less), CMAP amplitude (4 mV or less or greater than 4 mV), or preceding cytomegalovirus infection. Consequently, neither trial identified subgroups in which intravenous methylprednisolone was more likely to be beneficial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis</HEADING>
<P>Because of the heterogeneity in the results from the primary outcome measure, mean improvement in disability grade after four weeks, we repeated the analysis following omission of the trials which did not have adequate allocation concealment (<LINK REF="STD-Bansal-1986" TYPE="STUDY">Bansal 1986</LINK>; <LINK REF="STD-Garcia-1985" TYPE="STUDY">Garcia 1985</LINK>; <LINK REF="STD-Shukla-1988" TYPE="STUDY">Shukla 1988</LINK>; <LINK REF="STD-Singh-1996" TYPE="STUDY">Singh 1996</LINK>). This reduced but did not remove the heterogeneity and made little difference to the result, which showed almost no difference between the treatment groups, MD 0.01 (95% CI -0.37 to 0.39) more improvement in the corticosteroid-treated participants. We have described results of the separate analyses of the intravenous and oral regimens above. There was no evidence of heterogeneity in the other analyses.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-10-03 15:22:56 +0100" MODIFIED_BY="Ruth Brassington">
<P>We included eight studies examining the effects of corticosteroids in 653 participants. This is a relatively small number in relation to the known variability of severity and outcome of Guillain-Barré syndrome (GBS). Our primary outcome measure, mean disability grade improvement after four weeks, was available for six trials with 587 participants and showed no significant difference. There was significant heterogeneity in the results, which could be explained by considering separately the results of the trials that tested oral and intravenous corticosteroids. In the four trials of oral corticosteroids, with 120 participants, there was less improvement in the corticosteroid groups than in the control groups, which was highly significant. In the meta-analysis of the two trials of intravenous methylprednisolone, there was a non-significant trend towards benefit from corticosteroids. No significant differences emerged from our analyses of the secondary outcome measures selected for this review. These were the number improving after four weeks, the time to walk unaided, duration of ventilation (for ventilated participants), number of deaths, and number left dead or disabled (unable to walk unaided) after one year).</P>
<P>There were differences between the two trials of intravenous methylprednisolone that provided the bulk of the evidence. Both tested intravenous methylprednisolone 500 mg daily for five days against placebo. One reported no difference in any outcome between the corticosteroid-treated and placebo-treated groups (<LINK REF="STD-GBS-Steroid-1993" TYPE="STUDY">GBS Steroid 1993</LINK>). The other differed, in that both treatment groups also received intravenous immunoglobulin (IVIg), which has now become a standard treatment for GBS (<LINK REF="STD-van-Koningsveld-2004" TYPE="STUDY">van Koningsveld 2004</LINK>). Their raw results were not significant for any of the outcome measures, but further analyses taking into account age and disability at randomisation showed a borderline significant result for their primary outcome measure (proportion of participants improving by one or more disability grade after four weeks). The review authors judged the methodological quality of both trials adequate, but there was one caveat about <LINK REF="STD-GBS-Steroid-1993" TYPE="STUDY">GBS Steroid 1993</LINK>. Because of the variation in practice and ethical issues at the time of the trial, there was an imbalance in the numbers of participants who received plasma exchange in the two groups. Only 66 of 124 (53%) participants treated with intravenous methylprednisolone received plasma exchange compared with 77 of 118 (65%) placebo-treated participants (P = 0.08). Furthermore, the physicians caring for the participants in that trial had been asked at the time of randomisation to declare whether each participant would definitely, definitely not, or possibly receive plasma exchange. For those participants for whom plasma exchange had been declared possible, only 8 of 45 (17.8%) randomised to intravenous methylprednisolone eventually received plasma exchange compared with 15 of 32 (46.9%) placebo-treated participants (P = 0.0125). Since plasma exchange has been shown to be more effective than supportive treatment (<LINK REF="REF-GBS-Group-1985" TYPE="REFERENCE">GBS Group 1985</LINK>; <LINK REF="REF-Rapha_x00eb_l-2012" TYPE="REFERENCE">Raphaël 2012</LINK>), this imbalance could have biased the results against detection of a beneficial effect from corticosteroids. However, an analysis after excluding the participants in whom the use of plasma exchange had been declared possible showed no beneficial effect from corticosteroids according to trial authors.</P>
<P>Since analyses of <LINK REF="STD-van-Koningsveld-2004" TYPE="STUDY">van Koningsveld 2004</LINK> taking into account some prognostic factors showed significant differences in favour of corticosteroids for the primary outcome measure, the number of participants improving one disability grade after four weeks, we undertook a similar analysis of <LINK REF="STD-GBS-Steroid-1993" TYPE="STUDY">GBS Steroid 1993</LINK> taking into account age and disability, the factors for which we had information. We then used the inverse variance method to combine the results of these two trials taking into account these two factors; the log OR was in favour of corticosteroid group but the result was not significant.</P>
<P>The difference between the effects of oral and intravenous corticosteroids was unexpected. Multiple factors may play a role in this finding. The first question is whether the effect is real. The trials of oral corticosteroids that contributed the available evidence were of lower quality: in only two of the four trials was allocation concealment adequate. Second, the numbers in each trial were small; the total number of participants was only 120. Third, the unfavourable effect of oral corticosteroids was only detected for our primary outcome and not for improvement by one grade or for death, the only other outcomes for which data were available and where there was no difference. Fourth, corticosteroids are readily absorbed and the route of administration itself is unlikely to be responsible. Fifth, the oral corticosteroid courses lasted more than two weeks in all four trials since the treatment could be continued longer at the discretion of the treating physician. The intravenous courses only lasted five days. It is possible that early corticosteroid treatment helps by reducing inflammation and later treatment harms by inhibiting macrophage clearance of myelin debris or other repair mechanisms. Sixth, the intravenous trials tested higher initial doses, approximately eight-fold higher for the five days that they were given, and rapid intravenous infusion might have a different effect on the immune system compared with oral absorption from tablets.</P>
<P>The question now arises as to the data that provide the best evidence on which to base practice. Our analysis of the oral corticosteroid trials indicates an important negative effect that physicians caring for people with GBS will want to take into account. Our combined analysis of the intravenous methylprednisolone trials showed no significant difference in any outcome but one of the included trials did not use IVIg, which is now part of standard care. The only trial that has tested the effect of adding corticosteroids to IVIg is <LINK REF="STD-van-Koningsveld-2004" TYPE="STUDY">van Koningsveld 2004</LINK>; physicians may place more reliance on the data from this trial, which reflects current practice more accurately than the earlier studies. This argument assumes that corticosteroids given with IVIg are more efficacious than either treatment given on its own. However, there is a lack of other evidence to support this hypothesis. Whatever view is taken, the analyses presented in this review indicate that the true effect of intravenous corticosteroids is at best small and was absent for long-term outcomes.</P>
<P>Serious adverse events were infrequent with the short courses of corticosteroids used in these trials. This was not surprising since observational studies and clinical experience suggest that short courses of corticosteroids rarely cause serious adverse effects. The only differences in adverse events between groups in the two intravenous methylprednisolone trials were in increased blood glucose concentrations, which were, as expected, significantly more common; and in hypertension, which was, surprisingly, significantly less common in the intravenous methylprednisolone group than in the placebo group. This latter result is difficult to explain. An association between glomerulonephritis and GBS has been reported (<LINK REF="REF-Bettinelli-1989" TYPE="REFERENCE">Bettinelli 1989</LINK>; <LINK REF="REF-Olbricht-1993" TYPE="REFERENCE">Olbricht 1993</LINK>). It is possible that intravenous methylprednisolone had a favourable effect on renal function so as to prevent hypertension. Future trials of immunomodulatory treatment in GBS should monitor blood pressure and renal function. Few studies formally recorded the absence of the adverse events selected for consideration in this review. Particular adverse events that were recorded have been included but this list may be incomplete. Consequently, the absence of evidence cannot be construed as the absence of occurrence of these events. We encourage organisers of future trials to collect systematically information about adverse events and disease complications that are known to occur with GBS, such as infections requiring antibiotics, cardiac arrhythmia requiring insertion of a pacemaker or use of anti-arrhythmic drugs, postural hypotension, systemic hypertension requiring treatment, deep vein thrombosis, and pulmonary embolism.</P>
<P>Our searches for this review were comprehensive and it is unlikely that there are any significant unpublished trials. There are also no ongoing trials.</P>
<P>This review prompts recommendations about the design of future GBS trials. There is no information about whether the response to corticosteroids, or any other treatment, differs between the principal subtypes of GBS, acute inflammatory demyelinating polyradiculoneuropathy and acute motor axonal neuropathy. Possible differences should be investigated. In the trials reviewed, the principal outcome measures have involved crude clinical end points, or a simple disability scale that may seem rather coarsely graded to consumers and may be insufficiently responsive to detect meaningful clinical effects. Furthermore, the principally used GBS disability score is an ordinal scale in which the distances between different score points are unlikely to be comparably important. Future trials should incorporate more responsive, validated linear disability scales, such as the Rasch ordered disability scale, which has been validated for use in GBS (<LINK REF="REF-van-Nes-2011" TYPE="REFERENCE">van Nes 2011</LINK>). The present GBS disability scale should still be retained for comparison but might be relegated to a secondary outcome. Linear measures of strength, in particular grip strength, should also be considered. Electrophysiological outcome measures have not been used and might provide objective surrogate end points, having continuous scales that would allow the use of parametric statistics. However, such measures may not reflect disability or handicap and are affected by difficulties in standardisation between laboratories, which would make it difficult to draw useful conclusions. Future trials should consider measuring fatigue, which is a persistent problem in many people with GBS. No trial has included health-related quality of life measures or incorporated cost-effectiveness calculations. Since corticosteroids are inexpensive, cost would not be a significant bar to their use in GBS.</P>
<P>The absence of an easily demonstrable beneficial effect of corticosteroids in GBS is difficult to explain. GBS resembles the animal model of experimental autoimmune neuritis in which early treatment with high-dose corticosteroids does suppress the clinical deficit and hasten recovery (<LINK REF="REF-Hughes-1981" TYPE="REFERENCE">Hughes 1981</LINK>; <LINK REF="REF-King-1985" TYPE="REFERENCE">King 1985</LINK>; <LINK REF="REF-Watts-1989" TYPE="REFERENCE">Watts 1989</LINK>). In addition, the related condition, chronic inflammatory demyelinating polyradiculoneuropathy, showed a significant response to oral prednisone in the only RCT ever performed (<LINK REF="REF-Dyck-1982" TYPE="REFERENCE">Dyck 1982</LINK>; <LINK REF="REF-Mehndiratta-2015" TYPE="REFERENCE">Mehndiratta 2015</LINK>). It is possible that the anticipated beneficial effects of suppressing the inflammatory response that underlies the pathology of most cases of GBS in North America and Europe is counteracted by some other unexpected and unwanted effect of corticosteroids on the repair process. Following nerve transection in the rat, administration of corticosteroids causes prolonged loss of muscle electrical excitability due to loss of sodium channels or activation of calcium release channels (<LINK REF="REF-Rich-1998" TYPE="REFERENCE">Rich 1998</LINK>; <LINK REF="REF-Riggs-1998" TYPE="REFERENCE">Riggs 1998</LINK>). The same phenomenon, if it occurs in humans, would explain why the use of corticosteroids in severe cases of GBS, in which denervation is anticipated, does not have the beneficial effect predicted from its known anti-inflammatory properties. If this hypothesis is correct, then corticosteroids might be beneficial in a subgroup of people with conduction block but not denervation. In practice, it would be difficult to identify people in whom denervation is not already occurring or is about to occur. It would be helpful to develop indicators that would reliably identify people with GBS destined to have a poor prognosis.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-10-03 15:22:57 +0100" MODIFIED_BY="Ruth Brassington">
<IMPLICATIONS_PRACTICE MODIFIED="2016-10-03 15:22:57 +0100" MODIFIED_BY="Ruth Brassington">
<P>According to moderate quality evidence, corticosteroids do not significantly hasten recovery from GBS or affect the long-term outcome. There is low quality evidence to suggest that oral corticosteroids delay recovery and moderate quality evidence that intravenous corticosteroids given in combination with intravenous immunoglobulin might hasten recovery. There was no evidence of harm from corticosteroids except that increased blood glucose concentrations requiring insulin were significantly more common. Unexpectedly, hypertension was significantly less common.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-09-20 14:25:53 +0100" MODIFIED_BY="Ruth Brassington">
<P>More research into more effective treatments for Guillain-Barré syndrome should be undertaken. More responsive outcome measures should be designed and validated. Future trials should report serious complications of GBS as well as possible side effects of drugs. They should also report separately results in different subtypes of GBS and subgroups of patients having clinical features at randomisation that are known to affect prognosis. This would require large groups of participants. An explanation should be sought for the absence of more benefit from corticosteroids in GBS.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-10-03 15:22:57 +0100" MODIFIED_BY="Ruth Brassington">
<P>We thank Professor F van der Meché, co-author of the first version of this review, Dr R van Koningsveld co-author of the second version, and Dr A Swan co-author of the first three updates. RACH and PvD have consultancies with firms that manufacture human immunoglobulin (see <LINK TAG="CONFLICT_OF_INTEREST" TYPE="SECTION">Declarations of interest</LINK>), a drug used in the treatment of GBS. This review did not consider the comparison of corticosteroids and human immune globulin.</P>
<P>This project was supported by the United Kingdom National Institute for Health Research (NIHR) via Cochrane Infrastructure funding to Cochrane Neuromuscular. The views and opinions expressed therein are those of the review authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service, or the Department of Health. Cochrane Neuromuscular is also supported by the MRC Centre for Neuromuscular Diseases in the Institute of Neurology, University College London.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-10-03 15:54:26 +0100" MODIFIED_BY="Ruth Brassington">
<P>Richard Hughes holds consultancies with CSL Behring and LFB which make immunoglobulin which is used for treating GBS. He was chief investigator of one of the trials included in this review and an investigator in another.</P>
<P>RB is Managing Editor of Cochrane Neuromuscular. She has no known financial conflicts of interest. She did not take part in the approval processes for this review.</P>
<P>Angela Gunn is the Information Specialist of Cochrane Neuromuscular. She did not take part in the approval processes for this review.</P>
<P>PvD and his institution have received consultancy fees from Talecris, Octapharma, and CSL Behring for membership of the Scientific Board of the ICE trial in CIDP, intravenous immunoglobulin (IVIg) in chronic polyneuropathy and a trial of IVIg in CIDP.</P>
<P>PvD's department has received research grants from Baxter, Sanquin, Talecris, and Baxalta, respectively, to conduct the following: an RCT comparing IVIg vs IVIg and steroids in GBS, an RCT investigating the effect of a second course of IVIg (SID-trial) in GBS patients with a poor prognosis, a prospective international study on the effect of a second course of IVIg in GBS patients with a poor prognosis. and a dose-finding study in CIDP.</P>
<P>PvD was an investigator in a trial of corticosteroids in GBS (<LINK REF="STD-van-Koningsveld-2004" TYPE="STUDY">van Koningsveld 2004</LINK>).</P>
<P>The Co-ordinating Editor of Cochrane Neuromuscular has assessed the authors' declarations of interest and considers that they do not represent a conflict in relation to this review. Additionally, the review does not consider comparisons of corticosteroids with intravenous immunoglobulin.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-10-03 15:22:58 +0100" MODIFIED_BY="Ruth Brassington">
<P>RH prepared the first draft of the initial review and extracted the data from the studies.</P>
<P>PvD checked the data for the update of the review in January 2004.</P>
<P>RH and RvK undertook data extraction for the update in 2005.</P>
<P>AG undertook the searches in all versions of the review.</P>
<P>RH and PvD reviewed the results of the searches in 2009, 2011, and 2016.</P>
<P>RB edited the 2016 update.</P>
<P>All the current authors contributed to and agreed the 2016 update.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-08-08 16:26:16 +0100" MODIFIED_BY="KLJ ">
<P>In the 2009 update, RH and PvD reassessed risk of bias. The review authors added a 'Risk of bias' figure and 'Summary of findings' table and removed the previous Table of methodological quality.</P>
<P>Angela Gunn and Ruth Brassington became authors. Tony Swan was an author of the protocol and the original version of this review but retired before the 2012 update.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-10-04 10:23:10 +0100" MODIFIED_BY="Ruth Brassington">
<STUDIES MODIFIED="2016-10-03 15:27:59 +0100" MODIFIED_BY="Ruth Brassington">
<INCLUDED_STUDIES MODIFIED="2016-08-08 16:38:47 +0100" MODIFIED_BY="KLJ ">
<STUDY DATA_SOURCE="PUB" ID="STD-Bansal-1986" MODIFIED="2011-11-01 17:49:54 +0000" MODIFIED_BY="Angela A Gunn" NAME="Bansal 1986" YEAR="">
<REFERENCE MODIFIED="2011-11-01 17:49:54 +0000" MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bansal BC, Sood AK, Gupta AK, Yadav P</AU>
<TI>Role of steroids in the treatment of Guillain Barre syndrome - a controlled trial</TI>
<SO>Neurology India</SO>
<YR>1986</YR>
<VL>34</VL>
<NO>5</NO>
<PG>329-35</PG>
<IDENTIFIERS MODIFIED="2011-11-01 17:49:54 +0000" MODIFIED_BY="Angela A Gunn"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3266381"/><IDENTIFIER MODIFIED="2011-11-01 17:49:54 +0000" MODIFIED_BY="Angela A Gunn" TYPE="EMBASE" VALUE="1987132329"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3266380"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia-1985" MODIFIED="2012-05-09 17:55:46 +0100" MODIFIED_BY="Ruth Brassington" NAME="Garcia 1985" YEAR="1985">
<REFERENCE MODIFIED="2012-05-09 17:55:46 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia AC, Vidal BE, Rebolledo FA, Texeira F, Ordaz FA, Futran YJ</AU>
<TI>Treatment of the acute phase of Guillain-Barre-Strohl syndrome with megadoses of methylprednisolone</TI>
<SO>Revista de Investigacion Clinica (Mexico City)</SO>
<YR>1985</YR>
<VL>37</VL>
<PG>119-24</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3266383"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3266382"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-GBS-Steroid-1993" MODIFIED="2015-04-27 17:42:54 +0100" MODIFIED_BY="Angela A Gunn" NAME="GBS Steroid 1993" YEAR="1993">
<REFERENCE MODIFIED="2015-04-27 17:42:54 +0100" MODIFIED_BY="Angela A Gunn" NOTES="&lt;p&gt;*Guillain-Barr&amp;#233; Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barr&amp;#233; syndrome. Lancet 1993;341:586-90.&lt;/p&gt;" NOTES_MODIFIED="2015-04-27 17:42:54 +0100" NOTES_MODIFIED_BY="Angela A Gunn" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Guillain-Barré Syndrome Steroid Trial Group</AU>
<TI>Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>341</VL>
<NO>8845</NO>
<PG>586-90</PG>
<IDENTIFIERS MODIFIED="2015-04-27 17:42:54 +0100" MODIFIED_BY="Angela A Gunn"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3266385"/><IDENTIFIER MODIFIED="2015-04-27 17:42:54 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="8094828"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Guillain-Barr&amp;#233; Syndrome Steroid Trial Group. Double-masked trial of intravenous methylprednisolone in Guillain-Barr&amp;#233; syndrome. [Abstract] J Neurol Neurosurg Psychiatry 1992;55:1214.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guillain-Barré Syndrome Steroid Trial Group</AU>
<TI>Double-masked trial of intravenous methylprednisolone in Guillain-Barré syndrome [Abstract]</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1992</YR>
<VL>55</VL>
<PG>1214</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3266386"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3266384"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Hughes-1978" MODIFIED="2012-05-09 18:01:49 +0100" MODIFIED_BY="Jane Batchelor" NAME="Hughes 1978" YEAR="1978">
<REFERENCE MODIFIED="2012-05-09 18:01:49 +0100" MODIFIED_BY="Jane Batchelor" NOTES="&lt;p&gt;Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial of prednisolone in acute polyneuropathy. Lancet 1978;2:750-753.&lt;/p&gt;" NOTES_MODIFIED="2012-05-09 18:01:49 +0100" NOTES_MODIFIED_BY="Jane Batchelor" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM</AU>
<TI>Controlled trial of prednisolone in acute polyneuropathy</TI>
<SO>Lancet</SO>
<YR>1978</YR>
<VL>2</VL>
<NO>8093</NO>
<PG>750-3</PG>
<IDENTIFIERS MODIFIED="2012-05-09 18:01:49 +0100" MODIFIED_BY="Jane Batchelor"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3266388"/><IDENTIFIER MODIFIED="2012-05-09 18:01:49 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="80682"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3266387"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shukla-1988" MODIFIED="2011-11-01 17:50:41 +0000" MODIFIED_BY="Angela A Gunn" NAME="Shukla 1988" YEAR="1988">
<REFERENCE MODIFIED="2011-11-01 17:50:41 +0000" MODIFIED_BY="Angela A Gunn" NOTES="&lt;p&gt;Shukla SK, Agarwal R, Gupta OP, Pande G, Mamta S. Double blind controlled trial of prednisolone in Guillain-Barr&amp;#233; syndrome - a clinical study. Clinician - India 1988;52:128-34.&lt;/p&gt;" NOTES_MODIFIED="2011-11-01 17:50:41 +0000" NOTES_MODIFIED_BY="Angela A Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shukla SK, Agarwal R, Gupta OP, Pande G, Singh M</AU>
<TI>Double blind controlled trial of prednisolone in Guillain-Barré syndrome - a clinical study</TI>
<SO>Clinician - India</SO>
<YR>1988</YR>
<VL>52</VL>
<NO>5</NO>
<PG>128-34</PG>
<IDENTIFIERS MODIFIED="2011-11-01 17:50:41 +0000" MODIFIED_BY="Angela A Gunn"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3266390"/><IDENTIFIER MODIFIED="2011-11-01 17:50:41 +0000" MODIFIED_BY="Angela A Gunn" TYPE="EMBASE" VALUE="1988186155"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3266389"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singh-1996" MODIFIED="2011-11-01 17:44:42 +0000" MODIFIED_BY="Jane Batchelor" NAME="Singh 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-11-01 17:44:42 +0000" MODIFIED_BY="Jane Batchelor" NOTES="&lt;p&gt;Singh NK, Gupta A. Do corticosteroids influence the disease course or mortality in Guillain-Barr&amp;#233; syndrome? J Ass Physicians India 1996;44:22-4.&lt;/p&gt;" NOTES_MODIFIED="2011-11-01 17:44:42 +0000" NOTES_MODIFIED_BY="Jane Batchelor" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singh NK, Gupta A</AU>
<TI>Do corticosteroids influence the disease course or mortality in Guillain-Barré syndrome?</TI>
<SO>Journal of the Associations of Physicians of India</SO>
<YR>1996</YR>
<VL>44</VL>
<NO>1</NO>
<PG>22-4</PG>
<IDENTIFIERS MODIFIED="2011-11-01 17:44:42 +0000" MODIFIED_BY="Jane Batchelor"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3266392"/><IDENTIFIER MODIFIED="2011-11-01 17:44:42 +0000" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="8773088"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3266391"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swick-1976" MODIFIED="2012-05-09 18:02:00 +0100" MODIFIED_BY="Jane Batchelor" NAME="Swick 1976" YEAR="1976">
<REFERENCE MODIFIED="2012-05-09 18:02:00 +0100" MODIFIED_BY="Jane Batchelor" NOTES="&lt;p&gt;Swick HM, McQuillen MP. The use of steroids in the treatment of idiopathic polyneuritis. Neurology 1976;26:205-12.&lt;/p&gt;" NOTES_MODIFIED="2012-05-09 18:02:00 +0100" NOTES_MODIFIED_BY="Jane Batchelor" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swick HM, McQuillen MP</AU>
<TI>The use of steroids in the treatment of idiopathic polyneuritis</TI>
<SO>Neurology</SO>
<YR>1976</YR>
<VL>26</VL>
<NO>3</NO>
<PG>205-12</PG>
<IDENTIFIERS MODIFIED="2012-05-09 18:02:00 +0100" MODIFIED_BY="Jane Batchelor"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3266394"/><IDENTIFIER MODIFIED="2012-05-09 18:02:00 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="175314"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-11-01 17:48:55 +0000" MODIFIED_BY="Angela A Gunn"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3266393"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-van-Koningsveld-2004" MODIFIED="2016-08-08 16:38:47 +0100" MODIFIED_BY="KLJ " NAME="van Koningsveld 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-08-08 16:38:47 +0100" MODIFIED_BY="KLJ " PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruts L, van Koningsveld R, Jacobs BC, van Doorn PA</AU>
<TI>Determination of pain and response to methylprednisolone in Guillain-Barre syndrome</TI>
<SO>Journal of Neurology</SO>
<YR>2007</YR>
<VL>254</VL>
<NO>10</NO>
<PG>1318-22</PG>
<IDENTIFIERS MODIFIED="2015-04-27 17:43:54 +0100" MODIFIED_BY="Angela A Gunn"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4142258"/><IDENTIFIER MODIFIED="2015-04-27 17:43:54 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="17426908"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-08-08 16:38:39 +0100" MODIFIED_BY="KLJ " PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Doorn PA, van Koningsveld R, Schmitz PIM, van der Meché FGA, Visser LH, Meulstee J</AU>
<TI>Randomized trial on the effect of methyl prednisolone on standard treatment with intravenous immunoglobulin in Guillain-Barré syndrome</TI>
<SO>Neuromuscular Disorders</SO>
<YR>2002</YR>
<VL>12</VL>
<PG>781</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4142256"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-08-08 16:38:30 +0100" MODIFIED_BY="KLJ " PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Koningsveld R, Schmitz PIM, van der Meché FGA, Visser VH, Meulstee J, van Doorn PA</AU>
<TI>Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>363</VL>
<NO>9404</NO>
<PG>192-6</PG>
<IDENTIFIERS MODIFIED="2011-11-01 17:44:03 +0000" MODIFIED_BY="Angela A Gunn"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4142257"/><IDENTIFIER MODIFIED="2011-11-01 17:44:03 +0000" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="14738791"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4142255"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-10-03 15:27:59 +0100" MODIFIED_BY="Ruth Brassington">
<STUDY DATA_SOURCE="PUB" ID="STD-El-Zunni-1997" NAME="El Zunni 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>El Zunni S, Prakash PS, Saiti KM, Busnaina IA</AU>
<TI>Guillain-Barré syndrome (GBS): an appraisal</TI>
<SO>Central African Journal of Medicine</SO>
<YR>1997</YR>
<VL>43</VL>
<NO>4</NO>
<PG>99-103</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3266400"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3266399"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Foyaca-2003" MODIFIED="2016-10-03 15:27:59 +0100" MODIFIED_BY="Ruth Brassington" NAME="Foyaca 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-10-03 15:27:59 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Foyaca H, Ibanez-Valdes L de F, Awotedu AA</AU>
<TI>Effect of prednisone on Guillain-Barré syndrome in HIV positive patients</TI>
<SO>Internet Journal of Neurology</SO>
<YR>2003</YR>
<VL>2</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3266402"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3266401"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haass-1988" MODIFIED="2009-11-02 14:39:16 +0000" MODIFIED_BY="Jane Batchelor" NAME="Haass 1988" YEAR="1988">
<REFERENCE MODIFIED="2009-11-02 14:39:16 +0000" MODIFIED_BY="Jane Batchelor" NOTES="&lt;p&gt;Haass A, Trabert W, Gressnich N, Schimrigk K. High-dose steroid therapy in Guillain-Barr&amp;#233; syndrome. J Neuroimmunol 1988;20:305-08.&lt;/p&gt;" NOTES_MODIFIED="2009-11-02 14:39:16 +0000" NOTES_MODIFIED_BY="Jane Batchelor" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haass A, Trabert W, Gressnich N, Schimrigk K</AU>
<TI>High-dose steroid therapy in Guillain-Barré syndrome</TI>
<SO>Journal of Neuroimmunology</SO>
<YR>1988</YR>
<VL>20</VL>
<NO>2-3</NO>
<PG>305-8</PG>
<IDENTIFIERS MODIFIED="2009-11-02 14:39:16 +0000" MODIFIED_BY="Jane Batchelor"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3266404"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3266403"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levchenko-1989" MODIFIED="2009-11-02 14:39:33 +0000" MODIFIED_BY="Jane Batchelor" NAME="Levchenko 1989" YEAR="1989">
<REFERENCE MODIFIED="2009-11-02 14:39:33 +0000" MODIFIED_BY="Jane Batchelor" NOTES="&lt;p&gt;Levchenko NI, Piradov MA, Pirogov VN. Plasmapheresis and hormone therapy in severe forms of Guillain- Barr&amp;#233; syndrome. Klin Med (Mosk) 1989;67:88-91.&lt;/p&gt;" NOTES_MODIFIED="2009-11-02 14:39:33 +0000" NOTES_MODIFIED_BY="Jane Batchelor" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levchenko NI, Piradov MA, Pirogov VN</AU>
<TI>Plasmapheresis and hormone therapy in severe forms of Guillain-Barré syndrome</TI>
<SO>Klinicheskaia Meditsina</SO>
<YR>1989</YR>
<VL>67</VL>
<NO>12</NO>
<PG>88-91</PG>
<IDENTIFIERS MODIFIED="2009-11-02 14:39:33 +0000" MODIFIED_BY="Jane Batchelor"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3266406"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3266405"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mendell-1985" MODIFIED="2009-11-02 14:45:24 +0000" MODIFIED_BY="Jane Batchelor" NAME="Mendell 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Mendell JR, Kissel JT, Kennedy MS, Grinvalsky HT, Pittman GL, Kyler RS, et al. Plasma exchange in acute inflammatory polyradiculoneuropathy. A controlled randomized trial. [Abstract] Ann Neurol 1983;14:122.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mendell JR, Kissel JT, Kennedy MS, Grinvalsky HT, Pittman GL, Kyler RS, et al</AU>
<TI>Plasma exchange in acute inflammatory polyradiculoneuropathy. A controlled randomized trial. [Abstract]</TI>
<SO>Annals of Neurology</SO>
<YR>1983</YR>
<VL>14</VL>
<PG>122</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3266408"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-02 14:45:24 +0000" MODIFIED_BY="Jane Batchelor" NOTES="&lt;p&gt;*Mendell JR, Kissel JT, Kennedy MS, Sahenk Z, Grinvalsky HT, Pittman GL, et al. Plasma exchange and prednisone in Guillain-Barr&amp;#233; syndrome. A controlled randomized trial. Neurology 1985;35:1551-5.&lt;/p&gt;" NOTES_MODIFIED="2009-11-02 14:45:24 +0000" NOTES_MODIFIED_BY="Jane Batchelor" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mendell JR, Kissel JT, Kennedy MS, Sahenk Z, Grinvalsky HT, Pittman GL, et al</AU>
<TI>Plasma exchange and prednisone in Guillain-Barré syndrome. A controlled randomized trial</TI>
<SO>Neurology</SO>
<YR>1985</YR>
<VL>35</VL>
<NO>11</NO>
<PG>1551-5</PG>
<IDENTIFIERS MODIFIED="2009-11-02 14:45:24 +0000" MODIFIED_BY="Jane Batchelor"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3266409"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3266407"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naylor-1986" MODIFIED="2009-12-11 15:02:15 +0000" MODIFIED_BY="Ruth Brassington" NAME="Naylor 1986" YEAR="1986">
<REFERENCE MODIFIED="2009-12-11 15:02:15 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naylor C, Dos Santos Werneck AL, Lacativa M</AU>
<TI>Comparative study on steroids use and non-use in the Guillain-Barré syndrome</TI>
<SO>Arquivos de Neuro-Psiquitria</SO>
<YR>1986</YR>
<VL>44</VL>
<NO>4</NO>
<PG>359-63</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3266411"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3266410"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zagar-1995" NAME="Zagar 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zagar M</AU>
<TI>Treatment of Guillain-Barré syndrome</TI>
<SO>Lijecnicki Vjesnik</SO>
<YR>1995</YR>
<VL>117</VL>
<NO>9-10</NO>
<PG>246-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3266413"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3266412"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2000" MODIFIED="2009-11-05 16:14:29 +0000" MODIFIED_BY="Ruth Brassington" NAME="Zhang 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-11-05 16:14:29 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang X, Xia J, Ye H</AU>
<TI>Effect of tripterygium polyglycoside on interleukin-6 in patients with Guillain-Barré syndrome</TI>
<SO>Chung-Kuo Chung Hsi Chieh Ho Tsa Chih</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>5</NO>
<PG>332-4</PG>
<IDENTIFIERS MODIFIED="2009-11-05 16:14:29 +0000" MODIFIED_BY="Ruth Brassington"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3266415"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3266414"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-10-03 15:27:59 +0100" MODIFIED_BY="Ruth Brassington">
<ADDITIONAL_REFERENCES MODIFIED="2016-10-03 15:27:59 +0100" MODIFIED_BY="Ruth Brassington">
<REFERENCE ID="REF-Asbury-1990" MODIFIED="2009-11-02 14:40:03 +0000" MODIFIED_BY="Jane Batchelor" NAME="Asbury 1990" TYPE="JOURNAL_ARTICLE">
<AU>Asbury AK, Cornblath DR</AU>
<TI>Assessment of current diagnostic criteria for Guillain-Barré syndrome</TI>
<SO>Annals of Neurology</SO>
<YR>1990</YR>
<VL>27</VL>
<NO>Suppl</NO>
<PG>21-4</PG>
<IDENTIFIERS MODIFIED="2009-11-02 14:40:03 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Bettinelli-1989" MODIFIED="2016-10-03 15:27:59 +0100" MODIFIED_BY="Ruth Brassington" NAME="Bettinelli 1989" TYPE="JOURNAL_ARTICLE">
<AU>Bettinelli A, Giani M, Rossi L, Bardare M, Longetti A, Ghio L, et al</AU>
<TI>Ex novo episodes of acute glomerulonephritis and Guillain-Barré syndrome: a case report</TI>
<SO>Clinical Nephrology</SO>
<YR>1989</YR>
<VL>31</VL>
<PG>269-73</PG>
<IDENTIFIERS MODIFIED="2009-11-02 14:40:12 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Bromberg-2004" NAME="Bromberg 2004" TYPE="JOURNAL_ARTICLE">
<AU>Bromberg MB, Carter O</AU>
<TI>Corticosteroid use in the treatment of neuromuscular disorders: empirical and evidence-based data</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>2004</YR>
<VL>30</VL>
<NO>1</NO>
<PG>20-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dutch-GBS-Group-1994" MODIFIED="2009-11-02 14:45:56 +0000" MODIFIED_BY="Jane Batchelor" NAME="Dutch GBS Group 1994" TYPE="JOURNAL_ARTICLE">
<AU>The Dutch Guillain-Barré Study Group</AU>
<TI>Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study</TI>
<SO>Annals of Neurology</SO>
<YR>1994</YR>
<VL>35</VL>
<NO>6</NO>
<PG>749-52</PG>
<IDENTIFIERS MODIFIED="2009-11-02 14:45:56 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Dyck-1982" MODIFIED="2009-11-02 14:41:03 +0000" MODIFIED_BY="Jane Batchelor" NAME="Dyck 1982" TYPE="JOURNAL_ARTICLE">
<AU>Dyck PJ, O'Brien PC, Oviatt KF, Dinapoli RP, Daube JR, Bartleson JD, et al</AU>
<TI>Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment</TI>
<SO>Annals of Neurology</SO>
<YR>1982</YR>
<VL>11</VL>
<NO>2</NO>
<PG>136-41</PG>
<IDENTIFIERS MODIFIED="2009-11-02 14:41:03 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-GBS-Group-1985" MODIFIED="2009-11-02 14:40:42 +0000" MODIFIED_BY="Jane Batchelor" NAME="GBS Group 1985" TYPE="JOURNAL_ARTICLE">
<AU>The Guillain-Barré Syndrome Study Group</AU>
<TI>Plasmapheresis and acute Guillain-Barré syndrome</TI>
<SO>Neurology</SO>
<YR>1985</YR>
<VL>35</VL>
<NO>8</NO>
<PG>1096-104</PG>
<IDENTIFIERS MODIFIED="2009-11-02 14:40:42 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-1981" MODIFIED="2009-11-02 14:42:16 +0000" MODIFIED_BY="Jane Batchelor" NAME="Hughes 1981" TYPE="JOURNAL_ARTICLE">
<AU>Hughes RAC, Kadlubowski M, Hufschmidt A</AU>
<TI>Treatment of acute inflammatory polyneuropathy</TI>
<SO>Annals of Neurology</SO>
<YR>1981</YR>
<VL>9</VL>
<NO>Suppl</NO>
<PG>125-33</PG>
<IDENTIFIERS MODIFIED="2009-11-02 14:42:16 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-1990" MODIFIED="2008-07-22 21:25:25 +0100" MODIFIED_BY="[Empty name]" NAME="Hughes 1990" TYPE="BOOK">
<AU>Hughes RAC</AU>
<SO>Guillain-Barré Syndrome</SO>
<YR>1990</YR>
<PB>Springer-Verlag</PB>
<CY>Heidelberg</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2014" MODIFIED="2016-08-08 16:39:09 +0100" MODIFIED_BY="KLJ " NAME="Hughes 2014" TYPE="COCHRANE_REVIEW">
<AU>Hughes RAC, Swan AV, van Doorn PA</AU>
<TI>Intravenous immunoglobulin for Guillain-Barré syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>9</NO>
<PB>John Wiley and Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2016-04-26 16:06:39 +0100" MODIFIED_BY="Ruth  Brassington"><IDENTIFIER MODIFIED="2016-04-26 16:06:39 +0100" MODIFIED_BY="Ruth  Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD002063.pub6"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-King-1985" MODIFIED="2009-11-02 14:42:40 +0000" MODIFIED_BY="Jane Batchelor" NAME="King 1985" TYPE="JOURNAL_ARTICLE">
<AU>King RH, Craggs RI, Gross MLP, Thomas PK</AU>
<TI>Effects of glucocorticoids on experimental allergic neuritis</TI>
<SO>Experimental Neurology</SO>
<YR>1985</YR>
<VL>87</VL>
<NO>1</NO>
<PG>9-19</PG>
<IDENTIFIERS MODIFIED="2009-11-02 14:42:40 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Mehndiratta-2015" MODIFIED="2016-08-08 16:39:18 +0100" MODIFIED_BY="KLJ " NAME="Mehndiratta 2015" TYPE="COCHRANE_REVIEW">
<AU>Mehndiratta MM, Hughes RAC</AU>
<TI>Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>1</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2016-04-26 16:08:07 +0100" MODIFIED_BY="Ruth  Brassington"><IDENTIFIER MODIFIED="2016-04-26 16:08:07 +0100" MODIFIED_BY="Ruth  Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD002062.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Olbricht-1993" MODIFIED="2012-06-12 09:48:42 +0100" MODIFIED_BY="Jane Batchelor" NAME="Olbricht 1993" TYPE="JOURNAL_ARTICLE">
<AU>Olbricht CJ, Stark E, Helmchen U, Schulze M, Brunkhorst R, Koch KM</AU>
<TI>Glomerulonephritis associated with inflammatory demyelinating polyradiculoneuropathy: a case report and review of the literature</TI>
<SO>Nephron</SO>
<YR>1993</YR>
<VL>64</VL>
<NO>1</NO>
<PG>139-41</PG>
<IDENTIFIERS MODIFIED="2009-11-02 14:43:11 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Osler-1960" MODIFIED="2009-12-11 14:30:36 +0000" MODIFIED_BY="Ruth Brassington" NAME="Osler 1960" TYPE="JOURNAL_ARTICLE">
<AU>Osler LD, Sidell AD</AU>
<TI>The Guillain-Barre syndrome; the need for exact diagnostic criteria</TI>
<SO>New England Journal of Medicine</SO>
<YR>1960</YR>
<VL>12</VL>
<NO>262</NO>
<PG>964-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peter-1996" MODIFIED="2009-11-02 14:43:25 +0000" MODIFIED_BY="Jane Batchelor" NAME="Peter 1996" TYPE="JOURNAL_ARTICLE">
<AU>Peter JV, Gnanamuthu C, Cherian AM, Prabhakar S</AU>
<TI>Outcomes in the Guillain-Barré syndrome: the role of steroids</TI>
<SO>Journal of the Association of Physicians of India</SO>
<YR>1996</YR>
<VL>44</VL>
<NO>3</NO>
<PG>172-4</PG>
<IDENTIFIERS MODIFIED="2009-11-02 14:43:25 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Rapha_x00eb_l-2012" MODIFIED="2016-08-08 16:39:29 +0100" MODIFIED_BY="KLJ " NAME="Raphaël 2012" TYPE="COCHRANE_REVIEW">
<AU>Raphaël JC, Chevret S, Hughes RAC, Annane D</AU>
<TI>Plasma exchange for Guillain-Barré syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>7</NO>
<PG>CD001798</PG>
<IDENTIFIERS MODIFIED="2016-04-26 16:30:05 +0100" MODIFIED_BY="Ruth  Brassington"><IDENTIFIER MODIFIED="2016-04-26 16:30:05 +0100" MODIFIED_BY="Ruth  Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD001798.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2016-10-03 15:27:59 +0100" MODIFIED_BY="Ruth Brassington" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rich-1998" MODIFIED="2009-11-02 14:44:15 +0000" MODIFIED_BY="Jane Batchelor" NAME="Rich 1998" TYPE="JOURNAL_ARTICLE">
<AU>Rich MM, Pinter MJ, Kraner SD, Barchi RL</AU>
<TI>Loss of electrical excitability in an animal model of acute quadriplegic myopathy</TI>
<SO>Annals of Neurology</SO>
<YR>1998</YR>
<VL>43</VL>
<NO>2</NO>
<PG>171-9</PG>
<IDENTIFIERS MODIFIED="2009-11-02 14:44:15 +0000" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Riggs-1998" MODIFIED="2008-07-22 21:25:00 +0100" MODIFIED_BY="[Empty name]" NAME="Riggs 1998" TYPE="JOURNAL_ARTICLE">
<AU>Riggs JE, Schochet SS Jr</AU>
<TI>Critical illness myopathy, steroids and cytochrome P450</TI>
<SO>Archives of Neurology</SO>
<YR>1998</YR>
<VL>55</VL>
<NO>12</NO>
<PG>1591</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ropper-1991" MODIFIED="2008-07-22 21:24:50 +0100" MODIFIED_BY="[Empty name]" NAME="Ropper 1991" TYPE="BOOK">
<AU>Ropper AH, Wijdicks EFM, Truax BT</AU>
<SO>Guillain-Barré Syndrome</SO>
<YR>1991</YR>
<PB>FA Davis Company</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Nes-2011" MODIFIED="2016-08-08 16:39:38 +0100" MODIFIED_BY="KLJ " NAME="van Nes 2011" TYPE="JOURNAL_ARTICLE">
<AU>van Nes SI, Vanhoutte EK, van Doorn PA, Hermans M, Bakkers M, Kuitwaard K, et al</AU>
<TI>Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies</TI>
<SO>Neurology</SO>
<YR>2011</YR>
<VL>76</VL>
<NO>4</NO>
<PG>337-45</PG>
<IDENTIFIERS MODIFIED="2012-05-09 18:10:09 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Walgaard-2011" MODIFIED="2016-08-08 16:39:51 +0100" MODIFIED_BY="KLJ " NAME="Walgaard 2011" TYPE="JOURNAL_ARTICLE">
<AU>Walgaard C, Lingsma HF, Ruts L, van Doorn PA, Steyerberg EW, Jacobs BC</AU>
<TI>Early recognition of poor prognosis in Guillain-Barré syndrome</TI>
<SO>Nature Neurology</SO>
<YR>2011</YR>
<VL>76</VL>
<NO>11</NO>
<PG>968-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Watts-1989" MODIFIED="2012-05-09 18:10:02 +0100" MODIFIED_BY="Jane Batchelor" NAME="Watts 1989" TYPE="JOURNAL_ARTICLE">
<AU>Watts PM, Taylor WA, Hughes RAC</AU>
<TI>High-dose methylprednisolone suppresses experimental allergic neuritis in the Lewis rat</TI>
<SO>Experimental Neurology</SO>
<YR>1989</YR>
<VL>103</VL>
<NO>1</NO>
<PG>101-4</PG>
<IDENTIFIERS MODIFIED="2012-05-09 18:10:02 +0100" MODIFIED_BY="Jane Batchelor"/>
</REFERENCE>
<REFERENCE ID="REF-Willison-2016" MODIFIED="2016-10-03 15:27:59 +0100" MODIFIED_BY="Ruth Brassington" NAME="Willison 2016" TYPE="JOURNAL_ARTICLE">
<AU>Willison HJ, Jacobs BC, van Doorn PA</AU>
<TI>Guillain-Barré syndrome</TI>
<SO>Lancet</SO>
<YR>2016</YR>
<VL>388</VL>
<NO>10045</NO>
<PG>717-27</PG>
<IDENTIFIERS MODIFIED="2016-05-11 19:09:15 +0100" MODIFIED_BY="Ruth  Brassington"><IDENTIFIER MODIFIED="2016-05-11 19:09:15 +0100" MODIFIED_BY="Ruth  Brassington" TYPE="DOI" VALUE="10.1016/S0140-6736(16)00339-1"/></IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-08-22 15:57:52 +0100" MODIFIED_BY="Anne Lawson">
<REFERENCE ID="REF-Hughes-2000" MODIFIED="2012-06-12 09:49:27 +0100" MODIFIED_BY="Ruth Brassington" NAME="Hughes 2000" TYPE="COCHRANE_REVIEW">
<AU>Hughes RAC, van der Meché FGA</AU>
<TI>Corticosteroids for Guillain-Barré syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-05-10 00:26:01 +0100" MODIFIED_BY="Ruth Brassington"><IDENTIFIER MODIFIED="2012-05-10 00:26:01 +0100" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD001446"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2006" MODIFIED="2012-06-12 09:49:41 +0100" MODIFIED_BY="Ruth Brassington" NAME="Hughes 2006" TYPE="COCHRANE_REVIEW">
<AU>Hughes RAC, Swan AV, van Koningsveld R, van Doorn PA</AU>
<TI>Corticosteroids for Guillain-Barré syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-05-10 00:23:59 +0100" MODIFIED_BY="Ruth Brassington"><IDENTIFIER MODIFIED="2012-05-10 00:23:59 +0100" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD001446.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2010" MODIFIED="2016-08-22 15:57:52 +0100" MODIFIED_BY="Anne Lawson" NAME="Hughes 2010" TYPE="COCHRANE_REVIEW">
<AU>Hughes RAC, Swan AV, van Doorn PA</AU>
<TI>Corticosteroids for Guillain-Barré syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-05-10 00:21:25 +0100" MODIFIED_BY="Ruth Brassington"><IDENTIFIER MODIFIED="2012-05-10 00:21:25 +0100" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD001446.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2012" MODIFIED="2016-08-08 16:40:15 +0100" MODIFIED_BY="KLJ " NAME="Hughes 2012" TYPE="COCHRANE_REVIEW">
<AU>Hughes RAC, van Doorn PA</AU>
<TI>Corticosteroids for Guillain-Barré syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2016-05-11 19:07:18 +0100" MODIFIED_BY="Ruth  Brassington"><IDENTIFIER MODIFIED="2016-05-11 19:07:18 +0100" MODIFIED_BY="Ruth  Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD001446.pub4"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-10-03 15:23:40 +0100" MODIFIED_BY="Ruth Brassington">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-10-03 15:23:34 +0100" MODIFIED_BY="Ruth Brassington" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Funding" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Conflicts of interest among primary investigators" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-10-03 15:23:06 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Bansal-1986">
<CHAR_METHODS MODIFIED="2009-12-11 14:39:11 +0000" MODIFIED_BY="Ruth Brassington">
<P>Open parallel-group controlled trial with alternate allocation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-03 15:23:04 +0100" MODIFIED_BY="Ruth Brassington">
<P>20 people with GBS defined according to criteria similar to those of <LINK REF="REF-Asbury-1990" TYPE="REFERENCE">Asbury 1990</LINK>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-03 15:23:04 +0100" MODIFIED_BY="Ruth Brassington">
<P>Prednisolone 15 mg 4 times daily for 4 days, 10 mg 4 times daily for 3 days, 10 mg 3 times daily for 10 days, and then tapered or no treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-03 15:23:04 +0100" MODIFIED_BY="Ruth Brassington">
<P>Multiple outcomes including changes in the disability grade of <LINK REF="STD-Hughes-1978" TYPE="STUDY">Hughes 1978</LINK> after 1, 2, 3, and 4 weeks and 3 months; disease duration; residual disability; death; relapse</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-08-08 16:26:24 +0100" MODIFIED_BY="KLJ ">
<P>Not stated</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-08-08 16:26:24 +0100" MODIFIED_BY="KLJ ">
<P>Not stated</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2016-10-03 15:23:06 +0100" MODIFIED_BY="Ruth Brassington">
<P>Single centre<BR/>Conducted in India<BR/>Mean (SD) age 54.5 (15.1) years in steroid group and 39.6 (14.4) years in control group. Unusually large improvements after 4 weeks in both groups, mean 2.4 grades in steroid group and 4.0 grades in control group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-03 15:23:09 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Garcia-1985">
<CHAR_METHODS MODIFIED="2009-12-11 14:39:11 +0000" MODIFIED_BY="Ruth Brassington">
<P>Open parallel-group controlled trial with alternate allocation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-03 15:23:08 +0100" MODIFIED_BY="Ruth Brassington">
<P>20 mostly adults with GBS defined according to criteria of <LINK REF="REF-Asbury-1990" TYPE="REFERENCE">Asbury 1990</LINK>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-11 14:39:11 +0000" MODIFIED_BY="Ruth Brassington">
<P>Intravenous methylprednisolone 1500 mg daily for 5 days versus supportive care</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-03 15:23:09 +0100" MODIFIED_BY="Ruth Brassington">
<P>Time to recovery: not significantly different between the 2 groups. After 6 months, 7 of 10 corticosteroid-treated participants had returned to work or resumed domestic duties at 95% of normal. No adverse effects attributable to corticosteroids were reported</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-08-08 16:30:15 +0100" MODIFIED_BY="KLJ ">
<P>Not stated</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-08-08 16:30:15 +0100" MODIFIED_BY="KLJ ">
<P>Not stated</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2009-12-11 14:39:11 +0000" MODIFIED_BY="Ruth Brassington">
<P>Single centre<BR/>Conducted in Mexico</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-03 15:23:10 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-GBS-Steroid-1993">
<CHAR_METHODS MODIFIED="2009-12-11 14:39:12 +0000" MODIFIED_BY="Ruth Brassington">
<P>Double-blind parallel-group randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-03 15:23:10 +0100" MODIFIED_BY="Ruth Brassington">
<P>242 adults with GBS diagnosed according to the criteria of <LINK REF="REF-Asbury-1990" TYPE="REFERENCE">Asbury 1990</LINK>. Unable to run. Disease onset &lt; 15 days</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-11 14:39:12 +0000" MODIFIED_BY="Ruth Brassington">
<P>Intravenous methylprednisolone 500 mg daily for 5 days or placebo infusions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-03 15:23:10 +0100" MODIFIED_BY="Ruth Brassington">
<P>Primary: 0.5 disability grade (<LINK REF="STD-Hughes-1978" TYPE="STUDY">Hughes 1978</LINK>) difference after 4 weeks. Secondary: 0.5 disability grade difference after 12 weeks, reduction of times to cease artificial ventilation, and to recover ability to walk unaided. After 4 weeks, mean (SD) disability grade improvement in corticosteroid group was 0.73 (1.21) grade compared with 0.8 (1.14) grade in the placebo group; difference 0.06 grade (95% CI -0.23 to 0.36)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-08-08 16:32:07 +0100" MODIFIED_BY="KLJ ">
<P>Funded by the British Medical Research Council</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-08-08 16:32:07 +0100" MODIFIED_BY="KLJ ">
<P>Not stated in the paper but none known</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2016-08-08 16:32:07 +0100" MODIFIED_BY="KLJ ">
<P>International multicentre<BR/>Plasma exchange permitted at the discretion of the participating neurologist</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-03 15:23:19 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Hughes-1978">
<CHAR_METHODS MODIFIED="2016-10-03 15:23:12 +0100" MODIFIED_BY="Ruth Brassington">
<P>Observer blinded parallel-group randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-03 15:23:12 +0100" MODIFIED_BY="Ruth Brassington">
<P>40 participants of any age with acute polyneuropathy of undetermined aetiology fulfilling criteria similar to those of <LINK REF="REF-Asbury-1990" TYPE="REFERENCE">Asbury 1990</LINK>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-03 15:23:16 +0100" MODIFIED_BY="Ruth Brassington">
<P>Prednisolone 15 mg 3 times daily for 1 week, 10 mg 3 times daily for 4 days, 5 mg 4 times daily for 3 days followed by continued treatment at discretion or no steroid treatment<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-03 15:23:16 +0100" MODIFIED_BY="Ruth Brassington">
<P>Changes in a 7-point disability grade scale after 1, 3, and 12 months; time to onset of improvement; time to recover ability for manual work; and proportion with residual disability were all measured. A primary outcome measure was not predefined. There were no significant differences at any of these times except for the subgroup of participants who were randomised within 1 week from the onset. In this subgroup, the 6 control participants improved by a mean (SD) of 2.5 (0.43) grades whereas the 10 corticosteroid participants only improved by 0.9 (0.46) grade (P &lt; 0.05)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-10-03 15:23:17 +0100" MODIFIED_BY="Ruth Brassington">
<P>Funded by the British Medical Research Council</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-08-08 16:32:58 +0100" MODIFIED_BY="KLJ ">
<P>Not stated in the paper but none known</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2016-10-03 15:23:19 +0100" MODIFIED_BY="Ruth Brassington">
<P>Multicentre in south-east England</P>
<P>It was decided during the trial that participants who had begun to improve before trial entry should be excluded and so 1 participant was removed from each group. The 4-week grade change SD is not in the paper and has been derived from the original data. 1 suicide in the control group was excluded by the authors from their analysis but has been included in the death table in this review. There were no significant differences at any of these times except for the subgroup of participants who were randomised within 1 week from the onset. In this subgroup, the 6 control participants improved by a mean (SD) of 2.5 (0.43) grades whereas the 10 corticosteroid participants only improved 0.9 (0.46) grade (P &lt; 0.05)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-03 15:23:23 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Shukla-1988">
<CHAR_METHODS MODIFIED="2009-12-11 14:39:12 +0000" MODIFIED_BY="Ruth Brassington">
<P>Double-blind randomised parallel-group controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-03 15:23:21 +0100" MODIFIED_BY="Ruth Brassington">
<P>16 participants with GBS fulfilling diagnostic criteria of <LINK REF="REF-Asbury-1990" TYPE="REFERENCE">Asbury 1990</LINK>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-03 15:23:22 +0100" MODIFIED_BY="Ruth Brassington">
<P>Prednisolone 60 mg daily in divided doses for 1 week, 40 mg daily for 1 week, 30 mg daily for 2 weeks, and thereafter at the discretion of the physician or identical appearing placebo tablets</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-03 15:23:23 +0100" MODIFIED_BY="Ruth Brassington">
<P>Changes in the disability grade of <LINK REF="STD-Hughes-1978" TYPE="STUDY">Hughes 1978</LINK> after 1, 4, and 6 weeks. After 4 weeks, 5 of 8 corticosteroid and 3 of 6 placebo participants had improved &#8805; 1 grades. 2 placebo participants dropped out</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-08-08 16:33:57 +0100" MODIFIED_BY="KLJ ">
<P>Not stated</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-08-08 16:33:57 +0100" MODIFIED_BY="KLJ ">
<P>Not stated</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2009-12-11 14:39:12 +0000" MODIFIED_BY="Ruth Brassington">
<P>Single centre<BR/>Conducted in India</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-03 15:23:25 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Singh-1996">
<CHAR_METHODS MODIFIED="2016-10-03 15:23:24 +0100" MODIFIED_BY="Ruth Brassington">
<P>Double-blind controlled parallel-group trial with participants allocated alternately to 1 blinded treatment or the other</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-03 15:23:24 +0100" MODIFIED_BY="Ruth Brassington">
<P>52 participants with GBS fulfilling the diagnostic criteria of <LINK REF="REF-Asbury-1990" TYPE="REFERENCE">Asbury 1990</LINK>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-11 14:39:13 +0000" MODIFIED_BY="Ruth Brassington">
<P>Prednisolone 40 mg twice daily for 2 weeks and thereafter gradually tapered or identical appearing placebo tablets</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-03 15:23:25 +0100" MODIFIED_BY="Ruth Brassington">
<P>Disability grade of <LINK REF="STD-Hughes-1978" TYPE="STUDY">Hughes 1978</LINK> after 2, 4, and 24 weeks. After 4 weeks, 14 of 22 placebo and 12 of 24 corticosteroid participants had improved &#8805; 1 grades. 6 dropped out</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-08-08 16:35:25 +0100" MODIFIED_BY="KLJ ">
<P>Not stated</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-08-08 16:35:26 +0100" MODIFIED_BY="KLJ ">
<P>Not stated</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2009-12-11 14:39:13 +0000" MODIFIED_BY="Ruth Brassington">
<P>Single centre<BR/>Conducted in India</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-03 15:23:29 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Swick-1976">
<CHAR_METHODS MODIFIED="2009-12-11 14:39:13 +0000" MODIFIED_BY="Ruth Brassington">
<P>Double-blind parallel-group randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-03 15:23:28 +0100" MODIFIED_BY="Ruth Brassington">
<P>38 participants with idiopathic polyneuritis diagnosed according to criteria of <LINK REF="REF-Osler-1960" TYPE="REFERENCE">Osler 1960</LINK>. People requiring artificial ventilation or with contraindications to steroids were excluded</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-11 14:39:13 +0000" MODIFIED_BY="Ruth Brassington">
<P>Active treatment for adults 100 units and children 2 units/kg aqueous ACTH intramuscularly daily for 10 days or equal volumes of diluent as placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-03 15:23:29 +0100" MODIFIED_BY="Ruth Brassington">
<P>Duration of hospitalisation, time to complete recovery. Excluding 1 participant who died in the ACTH group, the median time to recovery was 9.0 days in the placebo and 4.4 days in the ACTH group (P = 0.05)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-08-08 16:36:07 +0100" MODIFIED_BY="KLJ ">
<P>"Supported in part by Special Traineeship Award" from National Institutes of Health, USA</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-08-08 16:36:15 +0100" MODIFIED_BY="KLJ ">
<P>Not stated</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2009-12-11 14:39:13 +0000" MODIFIED_BY="Ruth Brassington">
<P>Single centre<BR/>Conducted in USA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-03 15:23:31 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-van-Koningsveld-2004">
<CHAR_METHODS MODIFIED="2009-12-11 14:39:14 +0000" MODIFIED_BY="Ruth Brassington">
<P>Double-blind parallel-group randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-03 15:23:30 +0100" MODIFIED_BY="Ruth Brassington">
<P>225 people with GBS fulfilling the diagnostic criteria of <LINK REF="REF-Asbury-1990" TYPE="REFERENCE">Asbury 1990</LINK>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-12 09:46:40 +0100" MODIFIED_BY="Ruth Brassington">
<P>All participants received IVIg 0.4 g/kg daily for 5 days and also either intravenous methylprednisolone 500 mg daily for 5 days or placebo infusions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-03 15:23:31 +0100" MODIFIED_BY="Ruth Brassington">
<P>Primary: improvement of 1 disability grade (modified after <LINK REF="STD-Hughes-1978" TYPE="STUDY">Hughes 1978</LINK>) after 4 weeks. Secondary: ability to walk unaided after 8 weeks, number of days to walk independently. After 4 weeks, 63 of 113 (56%) placebo-treated participants improved &#8805; 1 grades compared with 76 of 112 (68%) corticosteroid-treated participants (P = 0.06). See text for more details</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-08-08 16:36:57 +0100" MODIFIED_BY="KLJ ">
<P>Baxter Bioscience, Brussels, Belgium, provided financial support</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-08-08 16:37:00 +0100" MODIFIED_BY="KLJ ">
<P>Paper states "None declared"</P>
</CHAR_USER_DEF_2>
<CHAR_NOTES MODIFIED="2016-10-03 15:23:31 +0100" MODIFIED_BY="Ruth Brassington">
<P>Multicentre centre study in the Netherlands, Belgium, and Germany</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ACTH: adrenocorticotrophic hormone<BR/>CI: confidence interval<BR/>GBS: Guillain-Barré syndrome<BR/>IVIg: intravenous immunoglobulin<BR/>SD: standard deviation</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-10-03 15:23:40 +0100" MODIFIED_BY="Ruth Brassington" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2016-10-03 15:23:35 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-El-Zunni-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-03 15:23:35 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not an RCT. Observational study in which 5 participants with disability grade 1 or 2 were given placebo, 5 with disability grade 2 who were already on steroids were continued on them and 6 with disability grade 3 to 5 were given IVIg. 1 of the last 6 died. There was no significant difference in the amount of improvement in disability grade between the groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-03 15:23:37 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Foyaca-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-03 15:23:37 +0100" MODIFIED_BY="Ruth Brassington">
<P>The participants were 29 HIV-positive in a single South African centre randomly allocated to prednisone 1 mg/kg daily or placebo. After 36 days the mean (SD) improvement on the disability scale used in this review was significantly greater, 0.8 (0.676) in the 15 prednisone-treated and 0.07 (0.27) in the 14 placebo-treated participants, mean difference 0.73 (95% CI 0.33 to 1.13). 10 of 15 prednisone-treated and 1 of 14 placebo-treated participants had improved &#8805; 1 grades and the relative rate of improving by this amount was significant, 9.3 (95% CI 1.4 to 63.8). Follow-up data were not available for 1 placebo participant for unstated reasons</P>
<P>Allocation concealment unclear, diagnostic criteria inadequate (criteria in methods contradicted by inclusion of non-eligible participants described in discussion)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-11 14:39:14 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Haass-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-11 14:39:14 +0000" MODIFIED_BY="Ruth Brassington">
<P>Non-randomised open study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-03 15:23:38 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Levchenko-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-03 15:23:38 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not a trial of corticosteroid treatment but a personal series of people with severe GBS all treated with prednisolone or methylprednisolone, 8 with and 11 without plasma exchange as well</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-11 14:39:15 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Mendell-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-11 14:39:15 +0000" MODIFIED_BY="Ruth Brassington">
<P>Compared corticosteroids and plasma exchange against no treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-11 14:39:15 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Naylor-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-11 14:39:15 +0000" MODIFIED_BY="Ruth Brassington">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-11 14:39:15 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Zagar-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-11 14:39:15 +0000" MODIFIED_BY="Ruth Brassington">
<P>Review, not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-03 15:23:40 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Zhang-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-03 15:23:40 +0100" MODIFIED_BY="Ruth Brassington">
<P>Controlled trial comparing 22 participants treated with the Chinese herbal medicine Tripterygium with 21 treated with dexamethasone 15 mg to 20 mg intravenously for 15 days and then 5 mg to 10 mg daily for 7 days followed by oral prednisone 30 mg to 60 mg daily reduced by 5 mg to 10 mg every 2 weeks. Method of randomisation unclear. None of the outcomes selected for this review available. After 8 weeks, 20 of 22 improved in the Tripterygium group and 13 of 21 in the dexamethasone group. Tripterygium lowered serum interleukin-6 significantly</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>CI: confidence interval</P>
<P>GBS: Guillain-Barré syndrome</P>
<P>HIV: human immunodeficiency virus</P>
<P>IVIg: intravenous immunoglobulin</P>
<P>RCT: randomised controlled trial</P>
<P>SD: standard deviation</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-10-03 15:23:33 +0100" MODIFIED_BY="Ruth Brassington">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-10-03 15:23:31 +0100" MODIFIED_BY="Ruth Brassington" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 17:30:09 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Bansal-1986">
<DESCRIPTION>
<P>"Patients were randomised alternatively into two groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-03 15:23:11 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-GBS-Steroid-1993">
<DESCRIPTION>
<P>"A telephone call to the trial office led to allocation of a random code number for a patient, stratified in blocks of 12 for each centre"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 17:30:09 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Garcia-1985">
<DESCRIPTION>
<P>Alternate allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-08-08 16:34:45 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-Hughes-1978">
<DESCRIPTION>
<P>At entry participants were randomised to prednisolone or control treatment according to a central register. The central register was prepared from a table of random numbers by the trial statistician</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-11 14:39:12 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Shukla-1988">
<DESCRIPTION>
<P>"Patients were randomised: packets of drugs had been prepared and numbered randomly well in advance"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-03 15:23:26 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Singh-1996">
<DESCRIPTION>
<P>"Alternately randomized"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-12 09:46:32 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Swick-1976">
<DESCRIPTION>
<P>Random groups were established using a table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-03 15:23:31 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-van-Koningsveld-2004">
<DESCRIPTION>
<P>"We stratified randomisation according to age (&lt;50 or &#8805;50 years) because of its effect on prognosis. We used block randomisation with random block sizes of 4, 6, or 8 generated by computer. When a neurologist identified a participant, they phoned a 24-h hotline and were given a number, according to the randomisation list. The local hospital pharmacist subsequently prepared the trial medication (methylprednisolone or placebo), according to the randomisation number"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-10-03 15:23:26 +0100" MODIFIED_BY="Ruth Brassington" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 17:30:09 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Bansal-1986">
<DESCRIPTION>
<P>"Patients were randomised alternatively into two groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-03 15:23:11 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-GBS-Steroid-1993">
<DESCRIPTION>
<P>"A telephone call to the trial office led to allocation of a random code number for a patient, stratified in blocks of 12 for each centre. The number led to the pharmacy preparing a coded 100 ml bag of either 5% dextrose with 500 mg methylprednisolone or normal saline alone (placebo). The seals on the bags that contained no methylprednisolone were punctured so that the bags could not be distinguished"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 17:30:09 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Garcia-1985">
<DESCRIPTION>
<P>Alternate allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-08-08 16:34:45 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-Hughes-1978">
<DESCRIPTION>
<P>The treatment allocation was obtained by telephoning a central reference point</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-08-08 16:34:19 +0100" MODIFIED_BY="KLJ " RESULT="UNKNOWN" STUDY_ID="STD-Shukla-1988">
<DESCRIPTION>
<P>See above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-03 15:23:26 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Singh-1996">
<DESCRIPTION>
<P>"Alternately randomized"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-12 09:46:33 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Swick-1976">
<DESCRIPTION>
<P>Random groups were established using a table of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 17:30:13 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-van-Koningsveld-2004">
<DESCRIPTION>
<P>See above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2016-05-16 15:33:27 +0100" MODIFIED_BY="Ruth  Brassington" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1" REF_IDS="CMP-001.01 CMP-001.02 CMP-001.03 CMP-001.06 CMP-001.07 CMP-001.08 CMP-001.09 CMP-001.05">
<NAME>All outcomes except death</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2" REF_IDS="CMP-001.04 CMP-001.05">
<NAME>Death</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2016-10-03 15:23:27 +0100" MODIFIED_BY="Ruth Brassington" NO="8">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1" REF_IDS="CMP-001.01 CMP-001.02 CMP-001.03 CMP-001.05 CMP-001.06 CMP-001.07 CMP-001.08 CMP-001.09">
<NAME>All outcomes except death</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.02" NO="2" REF_IDS="CMP-001.04">
<NAME>Death</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-03 15:23:06 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Bansal-1986">
<DESCRIPTION>
<P>Control group received no treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-08-08 16:26:52 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-Bansal-1986">
<DESCRIPTION>
<P>Blinding was unlikely to affect reporting of death</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-08-08 16:32:39 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-GBS-Steroid-1993">
<DESCRIPTION>
<P>See above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-08-08 16:32:43 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-GBS-Steroid-1993">
<DESCRIPTION>
<P>See above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-08-08 16:30:23 +0100" MODIFIED_BY="KLJ " RESULT="NO" STUDY_ID="STD-Garcia-1985">
<DESCRIPTION>
<P>Control group received supportive care and no placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-08-08 16:30:23 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-Garcia-1985">
<DESCRIPTION>
<P>Reporting of death is unlikely to have been affected by inadequate blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-03 15:23:20 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Hughes-1978">
<DESCRIPTION>
<P>The comparison was of prednisolone versus no treatment. Assessments were made within 24 hours of entry by 1 of 2 assessors who had no knowledge of the treatment schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-08-08 16:33:35 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-Hughes-1978">
<DESCRIPTION>
<P>Death would not be affected by any deficiency in blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-08-08 16:34:22 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-Shukla-1988">
<DESCRIPTION>
<P>"Placebo tablets of the same size, shape and colour were given in the equivalent number and duration"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-08-08 16:34:24 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-Shukla-1988">
<DESCRIPTION>
<P>Reporting of death unlikely to be affected by blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-03 15:23:27 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Singh-1996">
<DESCRIPTION>
<P>"Alternately randomized", "identical placebo tablets"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-08-08 16:35:33 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-Singh-1996">
<DESCRIPTION>
<P>Reporting of death is unlikely to have been affected by inadequate blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-08-08 16:36:23 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-Swick-1976">
<DESCRIPTION>
<P>Placebo was an equal volume of the diluent for ACTH</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-08-08 16:36:29 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-Swick-1976">
<DESCRIPTION>
<P>Reporting of death unlikely to be affected by blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-08-08 16:37:05 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-van-Koningsveld-2004">
<DESCRIPTION>
<P>See above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-08-08 16:37:09 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-van-Koningsveld-2004">
<DESCRIPTION>
<P>Reporting of death unlikely to be affected by blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="GROUP" MODIFIED="2016-10-03 15:23:32 +0100" MODIFIED_BY="Ruth Brassington" NO="9">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-09.02" NO="2" REF_IDS="CMP-001.04">
<NAME>Death</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-09.01" NO="1" REF_IDS="CMP-001.01 CMP-001.02 CMP-001.03 CMP-001.05 CMP-001.06 CMP-001.07 CMP-001.08 CMP-001.09">
<NAME>All outcomes except death</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-03 15:23:07 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Bansal-1986">
<DESCRIPTION>
<P>Control group received no treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2016-08-08 16:26:35 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-Bansal-1986">
<DESCRIPTION>
<P>Blinding was unlikely to affect reporting of death</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-08-08 16:32:46 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-GBS-Steroid-1993">
<DESCRIPTION>
<P>See above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2016-08-08 16:32:48 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-GBS-Steroid-1993">
<DESCRIPTION>
<P>See above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-08-08 16:30:23 +0100" MODIFIED_BY="KLJ " RESULT="NO" STUDY_ID="STD-Garcia-1985">
<DESCRIPTION>
<P>Control group received supportive care and no placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2016-08-08 16:30:23 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-Garcia-1985">
<DESCRIPTION>
<P>Reporting of death is unlikely to have been affected by inadequate blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-03 15:23:20 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Hughes-1978">
<DESCRIPTION>
<P>The comparison was of prednisolone versus no treatment. Assessments were made within 24 hours of entry by 1 of 2 assessors who had no knowledge of the treatment schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2016-08-08 16:34:45 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-Hughes-1978">
<DESCRIPTION>
<P>Death would not be affected by any deficiency in blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-08-08 16:34:35 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-Shukla-1988">
<DESCRIPTION>
<P>"Assessments were made...by a doctor who had no knowledge of the treatment schedule"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2016-08-08 16:34:39 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-Shukla-1988">
<DESCRIPTION>
<P>Reporting of death unlikely to be affected by blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-03 15:23:27 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Singh-1996">
<DESCRIPTION>
<P>"Alternately randomized", "identical placebo tablets"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2016-08-08 16:35:40 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-Singh-1996">
<DESCRIPTION>
<P>Reporting of death is unlikely to have been affected by inadequate blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-08-08 16:36:33 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-Swick-1976">
<DESCRIPTION>
<P>Placebo was an equal volume of the diluent for ACTH</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2016-08-08 16:36:37 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-Swick-1976">
<DESCRIPTION>
<P>Reporting of death unlikely to be affected by blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2016-10-03 15:23:32 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-van-Koningsveld-2004">
<DESCRIPTION>
<P>Report states, "In most cases neurologists responsible for patients' day-to-day care were not involved in assessment of treatment effect. We therefore assumed that unmasking was not an important issue in this trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2016-08-08 16:37:18 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-van-Koningsveld-2004">
<DESCRIPTION>
<P>Reporting of death unlikely to be affected by blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-10-03 15:23:33 +0100" MODIFIED_BY="Ruth Brassington" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2" REF_IDS="CMP-001.04">
<NAME>Death</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1" REF_IDS="CMP-001.01 CMP-001.02 CMP-001.03 CMP-001.05 CMP-001.06 CMP-001.07 CMP-001.08 CMP-001.09">
<NAME>All outcomes except death</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-10-12 17:30:09 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Bansal-1986">
<DESCRIPTION>
<P>Follow-up for 12 weeks was complete</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-10-12 17:30:09 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Bansal-1986">
<DESCRIPTION>
<P>Follow-up for 12 weeks was complete</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-12 09:46:10 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-GBS-Steroid-1993">
<DESCRIPTION>
<P>2 participants were withdrawn because of incorrect diagnosis (botulism). All other participants (of 240) remained in the trial for 48 weeks and all outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-12-11 14:39:12 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-GBS-Steroid-1993">
<DESCRIPTION>
<P>See above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-03 15:23:09 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Garcia-1985">
<DESCRIPTION>
<P>No drop-outs were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2016-10-03 15:23:09 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Garcia-1985">
<DESCRIPTION>
<P>No drop-outs were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-08-22 15:59:07 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Hughes-1978">
<DESCRIPTION>
<P>1 of 22 prednisolone-treated participants and 3 of 22 controls were withdrawn. 1 from each group because they had been started on steroids before randomisation in contradiction of a protocol amendment, and 2 more participants were withdrawn from the control group: 1 because the diagnosis was later considered to be incorrect and 1 because prednisolone had been given before entry to the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2016-08-08 16:34:45 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-Hughes-1978">
<DESCRIPTION>
<P>Deaths reported in full</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-03 15:23:23 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Shukla-1988">
<DESCRIPTION>
<P>3 of 8 corticosteroid and 1 of 8 control participants were omitted at 4-week follow-up, including 1 from each group who died</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-10-12 17:30:12 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Shukla-1988">
<DESCRIPTION>
<P>Deaths were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-03 15:23:27 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Singh-1996">
<DESCRIPTION>
<P>6 of 52 participants dropped out. The reasons and treatment assignment were not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2016-08-08 16:35:50 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-Singh-1996">
<DESCRIPTION>
<P>Reporting of death is unlikely to have been affected by attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-03 15:23:29 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Swick-1976">
<DESCRIPTION>
<P>Data for the outcomes required by this review not provided. However, 1 participant in the ACTH group who died was not included in the analysis of time to recovery, which was the main analysis considered by the authors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2012-06-12 09:46:36 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Swick-1976">
<DESCRIPTION>
<P>Deaths were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-03 15:23:32 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-van-Koningsveld-2004">
<DESCRIPTION>
<P>Only 8 of 233 randomised participants were withdrawn, 4 from each group, and the withdrawals were for legitimate reasons that we judged unlikely to have biased the results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2016-10-03 15:23:33 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-van-Koningsveld-2004">
<DESCRIPTION>
<P>Only 8 of 233 randomised participants were withdrawn, 4 from each group, and the withdrawals were for legitimate reasons that we judged unlikely to have biased the results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-10-03 15:23:29 +0100" MODIFIED_BY="Ruth Brassington" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-03 15:23:08 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Bansal-1986">
<DESCRIPTION>
<P>Only disability grade was specified in methods and was reported in full. Disease duration, residual disability, death, and relapse were also reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-12 09:46:11 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-GBS-Steroid-1993">
<DESCRIPTION>
<P>See above. All outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-03 15:23:10 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Garcia-1985">
<DESCRIPTION>
<P>The only outcome described in the methods, the recovery curve, was reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-08-08 16:34:45 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-Hughes-1978">
<DESCRIPTION>
<P>All outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-08-08 16:34:44 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-Shukla-1988">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-08-08 16:35:54 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-Singh-1996">
<DESCRIPTION>
<P>Outcomes specified in methods reported. Primary outcome not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-03 15:23:29 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Swick-1976">
<DESCRIPTION>
<P>Selective reporting not applicable as data for the outcomes required by this review are not provided. However, 1 participant in the ACTH group who died was not included in the analysis of time to recovery, which was the main analysis considered by the authors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-12 09:46:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Koningsveld-2004">
<DESCRIPTION>
<P>All outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-10-03 15:23:11 +0100" MODIFIED_BY="Ruth Brassington" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 17:30:09 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Bansal-1986">
<DESCRIPTION>
<P>Insufficient information to judge</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-03 15:23:11 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-GBS-Steroid-1993">
<DESCRIPTION>
<P>"The proportion of patients for whom plasma exchange was stated as possible at randomisation and who then went on to have the procedure was significantly lower in the intravenous methylprednisolone group than in the placebo group (8/45 vs 15/32, p = 0.0125). Therefore it is possible that the patients on placebo were considered by their neurologists to be faring worse than those receiving IVMP and were therefore given plasma exchange; this would have had a beneficial effect and biased the analysis of the trial against detecting an effect of IVMP."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 17:30:10 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Garcia-1985">
<DESCRIPTION>
<P>Insufficient information to judge</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-08-08 16:34:45 +0100" MODIFIED_BY="KLJ " RESULT="YES" STUDY_ID="STD-Hughes-1978">
<DESCRIPTION>
<P>None detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 17:30:12 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Shukla-1988">
<DESCRIPTION>
<P>Insufficient information to judge</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 17:30:13 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Singh-1996">
<DESCRIPTION>
<P>Insufficient information to judge</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-09 18:52:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Swick-1976">
<DESCRIPTION>
<P>None detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-12 09:46:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Koningsveld-2004">
<DESCRIPTION>
<P>None detected</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2016-08-08 16:28:33 +0100" MODIFIED_BY="KLJ " NO="7">
<NAME>Blinding (death)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-10-03 15:23:43 +0100" MODIFIED_BY="Ruth Brassington">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-10-03 15:23:43 +0100" MODIFIED_BY="Ruth Brassington" NO="1" READONLY="YES">
<TITLE MODIFIED="2009-11-11 13:09:08 +0000" MODIFIED_BY="Grade Profiler">Corticosteroid versus control for Guillain-Barré syndrome</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Corticosteroid versus control for Guillain-Barré syndrome</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with Guillain-Barré syndrome<BR/>
<B>Settings:</B> hospital<BR/>
<B>Intervention:</B> corticosteroid versus control<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Corticosteroid </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Disability grade change after 4 weeks</B>
<BR/>GBS disability grade. Scale from: 0 to 6</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean disability grade change after 4 weeks in the control groups was<BR/>
<B>-0.89 GBS disability grade change</B>
<SUP>1</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean disability grade change after 4 weeks in the intervention groups was<BR/>
<B>0.36 lower</B>
<BR/>(0.88 lower to 0.16 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>587<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Lower change in disability grade means less improvement so the corticosteroid group did worse, but not significantly</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Disability grade change after 4 weeks - oral regimens</B>
<BR/>GBS disability grade. Scale from: 0 to 6</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean disability grade change after 4 weeks - oral regimens in the control groups was<BR/>
<B>-1.33 GBS disability grade</B>
<SUP>1</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean disability grade change after 4 weeks - oral regimens in the intervention groups was<BR/>
<B>0.82 lower</B>
<BR/>(1.47 to 0.17 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>120<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>3,4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Lower change in disability grade means less improvement so the corticosteroid group did worse, significantly in this analysis</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Disability grade change after 4 weeks - intravenous regimens</B>
<BR/>GBS disability grade. Scale from: 0 to 6</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean disability grade change after 4 weeks - intravenous regimens in the control groups was<BR/>
<B>-0.78 GBS disability grade</B>
<SUP>1</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean disability grade change after 4 weeks - intravenous regimens in the intervention groups was<BR/>
<B>0.17 higher</B>
<BR/>(0.39 higher to 0.06 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>467<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Higher change in disability grade means more improvement so the corticosteroid group did better, but not significantly</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Improvement by &#8805; 1 grades after 4 weeks</B>
<BR/>GBS disability grade scale</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>543 per 1000</B>
<SUP>7</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>586 per 1000</B>
<BR/>(505 to 673)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.08 </B>
<BR/>(0.93 to 1.24)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>567<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>8</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Slightly more corticosteroid participants improved but the difference was not significant</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Death or disability after 1 year</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>92 per 1000</B>
<SUP>7</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>139 per 1000</B>
<BR/>(84 to 230)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.51 </B>
<BR/>(0.91 to 2.5)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>491<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>9</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>More corticosteroid participants had died or were disabled but the difference was not significant</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events - diabetes mellitus requiring insulin</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>56 per 1000</B>
<SUP>7</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>124 per 1000</B>
<BR/>(67 to 231)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 2.21 </B>
<BR/>(1.19 to 4.12)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>467<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Significantly more corticosteroid participants needed insulin</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events - hypertension</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>117 per 1000</B>
<SUP>7</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>18 per 1000</B>
<BR/>(6 to 48)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.15 </B>
<BR/>(0.05 to 0.41)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>467<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Significantly fewer corticosteroid participants developed hypertension, the opposite of what was expected. See <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>GBS:</B> Guillain-Barré syndrome; <B>RR:</B> risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Based on mean scores of control groups.<BR/>
<SUP>2</SUP> We downgraded once for imprecision. 95% CI consistent with either a clinically significant 0.88 grade less improvement with corticosteroids or slight benefit. High heterogeneity but not downgraded because explained by route of administration.<BR/>
<SUP>3</SUP> We downgraded because of limitations in study design. 3 of 4 trials had inadequate allocation concealment and 3 of 4 inadequate blinding.<BR/>
<SUP>4</SUP> We downgraded for heterogeneity; the I<SUP>2</SUP> test for heterogeneity was 51%.<BR/>
<SUP>5</SUP> We downgraded for imprecision. Wide CIs consistent with no difference or clinically significant worse outcome with corticosteroids.<BR/>
<SUP>6</SUP> We downgraded for limitations in design and implementation. In 1 of the trials, plasma exchange was used more often in the placebo group, which might have biased against detecting the efficacy of corticosteroids. See <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK>.<BR/>
<SUP>7</SUP> Based on mean of control participants in all studies.<BR/>
<SUP>8</SUP> We downgraded once for limitations in design and implementation of the studies. 3 of 6 trials had inadequate allocation concealment, 3 inadequate blinding and in 1, more placebo than corticosteroid participants received plasma exchange which might have biased against detecting an effect from corticosteroids.</P>
<P>
<SUP>9</SUP> We downgraded for limitations in design and implementation of the studies and for imprecision.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2009-07-14 18:45:48 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-10-03 15:27:59 +0100" MODIFIED_BY="Ruth Brassington">
<COMPARISON ID="CMP-001" MODIFIED="2016-10-03 15:27:59 +0100" MODIFIED_BY="Ruth Brassington" NO="1">
<NAME>Corticosteroid (CS) versus control</NAME>
<CONT_OUTCOME CHI2="24.596084203963088" CI_END="0.88278796724052" CI_START="-0.16382851033715984" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="0.3594797284516801" ESTIMABLE="YES" I2="79.67156089344348" I2_Q="87.3443748528651" ID="CMP-001.01" MODIFIED="2016-10-03 15:27:59 +0100" MODIFIED_BY="Ruth Brassington" NO="1" P_CHI2="1.6671491291575524E-4" P_Q="0.004939060573364129" P_Z="0.17818272358744516" Q="7.901624679728993" RANDOM="YES" SCALE="2.7" SORT_BY="USER" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.28675290678895" TOTALS="YES" TOTAL_1="297" TOTAL_2="290" UNITS="" WEIGHT="100.0" Z="1.3463715430282601">
<NAME>Disability grade change after 4 weeks</NAME>
<GROUP_LABEL_1>CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours CS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.163561787041947" CI_END="1.4680349441968947" CI_START="0.16912222992038128" DF="3" EFFECT_SIZE="0.818578587058638" ESTIMABLE="YES" I2="51.32684471003287" ID="CMP-001.01.01" MODIFIED="2016-05-11 20:41:58 +0100" MODIFIED_BY="Ruth  Brassington" NO="1" P_CHI2="0.10391822911379778" P_Z="0.0134980892755293" STUDIES="4" TAU2="0.21341731067101177" TOTAL_1="61" TOTAL_2="59" WEIGHT="54.55726840841167" Z="2.470350057423602">
<NAME>Oral regimens</NAME>
<CONT_DATA CI_END="1.0424809596528086" CI_START="-0.042480959652808625" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="-0.24" MEAN_2="-0.74" ORDER="1" SD_1="0.94" SD_2="0.81" SE="0.27678108574026317" STUDY_ID="STD-Hughes-1978" TOTAL_1="21" TOTAL_2="19" WEIGHT="19.619188379921177"/>
<CONT_DATA CI_END="2.3314002580611386" CI_START="0.8485997419388619" EFFECT_SIZE="1.5900000000000003" ESTIMABLE="YES" MEAN_1="-2.38" MEAN_2="-3.97" ORDER="2" SD_1="0.97" SD_2="0.7" SE="0.3782723886302039" STUDY_ID="STD-Bansal-1986" TOTAL_1="10" TOTAL_2="10" WEIGHT="16.58476025514356"/>
<CONT_DATA CI_END="1.814334582440334" CI_START="-1.3943345824403341" EFFECT_SIZE="0.20999999999999996" ESTIMABLE="YES" MEAN_1="-0.67" MEAN_2="-0.88" ORDER="3" SD_1="1.75" SD_2="1.13" SE="0.818553093370654" STUDY_ID="STD-Shukla-1988" TOTAL_1="6" TOTAL_2="8" WEIGHT="7.450851927776479"/>
<CONT_DATA CI_END="1.787552532971468" CI_START="-0.5875525329714679" EFFECT_SIZE="0.6000000000000001" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-0.8" MODIFIED="2016-05-11 20:41:58 +0100" MODIFIED_BY="Ruth  Brassington" ORDER="4" SD_1="2.0" SD_2="2.1" SE="0.6059052831270018" STUDY_ID="STD-Singh-1996" TOTAL_1="24" TOTAL_2="22" WEIGHT="10.902467845570456"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.9777126505556919" CI_END="0.05793675474433699" CI_START="-0.39252939263525044" DF="1" EFFECT_SIZE="-0.16729631894545674" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" NO="2" P_CHI2="0.32276438528965823" P_Z="0.14544736183240634" STUDIES="2" TAU2="0.0" TOTAL_1="236" TOTAL_2="231" WEIGHT="45.44273159158833" Z="1.4558020032653822">
<NAME>Intravenous regimens</NAME>
<CONT_DATA CI_END="0.2265204131930933" CI_START="-0.3665204131930934" EFFECT_SIZE="-0.07000000000000006" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="-0.73" ORDER="1" SD_1="1.14" SD_2="1.21" SE="0.1512887050639749" STUDY_ID="STD-GBS-Steroid-1993" TOTAL_1="124" TOTAL_2="118" WEIGHT="23.022911803610064"/>
<CONT_DATA CI_END="0.046296320212705355" CI_START="-0.6462963202127052" EFFECT_SIZE="-0.29999999999999993" ESTIMABLE="YES" MEAN_1="-1.13" MEAN_2="-0.83" ORDER="2" SD_1="1.3" SD_2="1.35" SE="0.17668504265601126" STUDY_ID="STD-van-Koningsveld-2004" TOTAL_1="112" TOTAL_2="113" WEIGHT="22.419819787978263"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.8887621658667966" CI_END="1.2430689804580544" CI_START="0.9297818829851684" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.075073493920645" ESTIMABLE="YES" EVENTS_1="167" EVENTS_2="152" I2="0.0" I2_Q="66.67167604350156" ID="CMP-001.02" LOG_CI_END="0.09449522920565594" LOG_CI_START="-0.031618920398818466" LOG_EFFECT_SIZE="0.031438154403418704" METHOD="MH" MODIFIED="2016-10-03 15:27:59 +0100" MODIFIED_BY="Ruth Brassington" NO="2" P_CHI2="0.42126967696600215" P_Q="0.0832415425728732" P_Z="0.3284836866388482" Q="3.000450911678736" RANDOM="NO" SCALE="5.0" SORT_BY="USER" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="287" TOTAL_2="280" WEIGHT="100.00000000000001" Z="0.9771726735557966">
<NAME>Improvement by &#8805; 1 grades after 4 weeks</NAME>
<GROUP_LABEL_1>CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CS</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.007266774501162107" CI_END="1.157672687631326" CI_START="0.5500769478720996" DF="2" EFFECT_SIZE="0.7980031695721078" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="29" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.06358578732843996" LOG_CI_START="-0.2595765546897813" LOG_EFFECT_SIZE="-0.09799538368067068" NO="1" P_CHI2="0.9963732055210102" P_Z="0.23456778792338406" STUDIES="3" TAU2="0.0" TOTAL_1="51" TOTAL_2="49" WEIGHT="19.136734810407134" Z="1.1886745309852296">
<NAME>Oral regimens</NAME>
<DICH_DATA CI_END="1.5638333917356735" CI_START="0.4239973567477511" EFFECT_SIZE="0.8142857142857143" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.1941904821611049" LOG_CI_START="-0.37263685084463577" LOG_EFFECT_SIZE="-0.08922318434176543" ORDER="1" O_E="0.0" SE="0.33295718124812246" STUDY_ID="STD-Hughes-1978" TOTAL_1="21" TOTAL_2="19" VAR="0.11086048454469508" WEIGHT="6.835847902164449"/>
<DICH_DATA CI_END="2.0967048268278794" CI_START="0.3052408673891694" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3215372949847304" LOG_CI_START="-0.5153573210008432" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="2" O_E="0.0" SE="0.49159604012508756" STUDY_ID="STD-Shukla-1988" TOTAL_1="6" TOTAL_2="8" VAR="0.2416666666666667" WEIGHT="2.7901420008834483"/>
<DICH_DATA CI_END="1.3081081501576224" CI_START="0.47193876033959586" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.11664365153793925" LOG_CI_START="-0.32611435257796517" LOG_EFFECT_SIZE="-0.104735350520013" ORDER="4" O_E="0.0" SE="0.2600782433051497" STUDY_ID="STD-Singh-1996" TOTAL_1="24" TOTAL_2="22" VAR="0.06764069264069265" WEIGHT="9.510744907359234"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7076407994567212" CI_END="1.3358791765105824" CI_START="0.9739414187535108" DF="1" EFFECT_SIZE="1.1406437044292088" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="123" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.12576718018471855" LOG_CI_START="-0.011467164555895802" LOG_EFFECT_SIZE="0.05715000781441137" NO="2" P_CHI2="0.4002285829248039" P_Z="0.10259130714672741" STUDIES="2" TAU2="0.0" TOTAL_1="236" TOTAL_2="231" WEIGHT="80.86326518959288" Z="1.6324187249794055">
<NAME>Intravenous regimens</NAME>
<DICH_DATA CI_END="1.3515066217819403" CI_START="0.8355059961574001" EFFECT_SIZE="1.0626344086021506" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="60" LOG_CI_END="0.13081817788995098" LOG_CI_START="-0.07805042896780462" LOG_EFFECT_SIZE="0.026383874461073157" ORDER="1" O_E="0.0" SE="0.12269045358452435" STUDY_ID="STD-GBS-Steroid-1993" TOTAL_1="124" TOTAL_2="118" VAR="0.015052947400776324" WEIGHT="40.03046705399724"/>
<DICH_DATA CI_END="1.4984014414246505" CI_START="0.9886412913331504" EFFECT_SIZE="1.2171201814058956" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="63" LOG_CI_END="0.17562818214779408" LOG_CI_START="-0.004961254866898582" LOG_EFFECT_SIZE="0.08533346364044773" ORDER="2" O_E="0.0" SE="0.10607912923456081" STUDY_ID="STD-van-Koningsveld-2004" TOTAL_1="112" TOTAL_2="113" VAR="0.011252781659162655" WEIGHT="40.832798135595645"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="1.9450112101910828" CI_END="0.72780060095617" CI_START="-0.046821747452985396" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="0.34048942675159233" ESTIMABLE="YES" I2="48.586414578980374" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.1379875901459901" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.4678963697269226" MODIFIED="2016-10-03 15:27:59 +0100" MODIFIED_BY="Ruth Brassington" NO="3" P_CHI2="0.16312573811242992" P_Q="1.0" P_Z="0.08488392126741408" Q="0.0" RANDOM="NO" SCALE="4.0" SHOW_PARTICIPANTS="NO" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2" TOTAL_2="2" WEIGHT="100.0" Z="1.7230254585872529">
<NAME>Treatment vs. control OR for improvement by &#8805; 1 grades by 4 weeks adjusted for age and initial disability grade</NAME>
<GROUP_LABEL_1>CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours steroid</GRAPH_LABEL_2>
<EFFECT_MEASURE>log(OR)</EFFECT_MEASURE>
<IV_DATA CI_END="0.6130902758258147" CI_START="-0.4452902758258147" EFFECT_SIZE="0.0839" ESTIMABLE="YES" ESTIMATE="0.0839" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" SE="0.27" STUDY_ID="STD-GBS-Steroid-1993" TOTAL_1="1" TOTAL_2="1" WEIGHT="53.566878980891715"/>
<IV_DATA CI_END="1.2048895555166157" CI_START="0.06811044448338421" EFFECT_SIZE="0.6365" ESTIMABLE="YES" ESTIMATE="0.6365" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" SE="0.29" STUDY_ID="STD-van-Koningsveld-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="46.433121019108285"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="1.5793150093170356" CI_END="2.4692103273752593" CI_START="0.667108008461875" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.283444577677121" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.39255808471849174" LOG_CI_START="-0.1758038457213872" LOG_EFFECT_SIZE="0.10837711949855229" METHOD="MH" MODIFIED="2012-05-09 21:47:04 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.9540529568677545" P_Q="0.5520314558039974" P_Z="0.45478308570933423" Q="0.35369083312344807" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="308" TOTAL_2="297" WEIGHT="100.00000000000001" Z="0.7474647388890355">
<NAME>Death</NAME>
<GROUP_LABEL_1>CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8356655345493409" CI_END="2.6293052962770123" CI_START="0.4125825745194035" DF="4" EFFECT_SIZE="1.0415399888316688" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.4198410162282862" LOG_CI_START="-0.3844891184614582" LOG_EFFECT_SIZE="0.017675948883413978" NO="1" P_CHI2="0.9336036721330291" P_Z="0.931351718079461" STUDIES="5" TAU2="0.0" TOTAL_1="72" TOTAL_2="66" WEIGHT="52.560614354468825" Z="0.0861442875503496">
<NAME>Oral regimens</NAME>
<DICH_DATA CI_END="13.867772482168174" CI_START="0.07210963413813187" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1420067079086855" LOG_CI_START="-1.1420067079086855" LOG_EFFECT_SIZE="0.0" ORDER="7263" O_E="0.0" SE="1.3416407864998738" STUDY_ID="STD-Bansal-1986" TOTAL_1="10" TOTAL_2="10" VAR="1.7999999999999998" WEIGHT="6.750665242523451"/>
<DICH_DATA CI_END="4.598004635829613" CI_START="0.04450811651697542" EFFECT_SIZE="0.4523809523809524" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6625694048006385" LOG_CI_START="-1.3515607836907813" LOG_EFFECT_SIZE="-0.3444956894450715" ORDER="7264" O_E="0.0" SE="1.183110042825089" STUDY_ID="STD-Hughes-1978" TOTAL_1="21" TOTAL_2="19" VAR="1.399749373433584" WEIGHT="14.176397009299247"/>
<DICH_DATA CI_END="13.366995426866405" CI_START="0.074811127562002" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.126033799470454" LOG_CI_START="-1.126033799470454" LOG_EFFECT_SIZE="0.0" ORDER="7265" O_E="0.0" SE="1.3228756555322954" STUDY_ID="STD-Shukla-1988" TOTAL_1="8" TOTAL_2="8" VAR="1.75" WEIGHT="6.750665242523451"/>
<DICH_DATA CI_END="4.861343809873834" CI_START="0.30728687764476315" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6867563368636589" LOG_CI_START="-0.5124559854258585" LOG_EFFECT_SIZE="0.0871501757189002" ORDER="7266" O_E="0.0" SE="0.7044232543095956" STUDY_ID="STD-Singh-1996" TOTAL_1="24" TOTAL_2="22" VAR="0.49621212121212116" WEIGHT="21.132517280942977"/>
<DICH_DATA CI_END="51.3197562011779" CI_START="0.11223747785200497" EFFECT_SIZE="2.4" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.710284584555295" LOG_CI_START="-0.9498621011320829" LOG_EFFECT_SIZE="0.38021124171160603" ORDER="7267" O_E="0.0" SE="1.5625833311112296" STUDY_ID="STD-Swick-1976" TOTAL_1="9" TOTAL_2="7" VAR="2.4416666666666664" WEIGHT="3.750369579179695"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4436608525421921" CI_END="3.9371348846874707" CI_START="0.6113681938530305" DF="1" EFFECT_SIZE="1.551463516621367" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.5951802938026736" LOG_CI_START="-0.21369715899139344" LOG_EFFECT_SIZE="0.19074156740564008" NO="2" P_CHI2="0.5053608144061894" P_Z="0.35529941147167743" STUDIES="2" TAU2="0.0" TOTAL_1="236" TOTAL_2="231" WEIGHT="47.43938564553119" Z="0.9243590637331108">
<NAME>Intravenous regimens</NAME>
<DICH_DATA CI_END="12.025498000253236" CI_START="0.47064948867750545" EFFECT_SIZE="2.379032258064516" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0801030704332817" LOG_CI_START="-0.32730240880142597" LOG_EFFECT_SIZE="0.3764003308159279" ORDER="7268" O_E="0.0" SE="0.8267169452719482" STUDY_ID="STD-GBS-Steroid-1993" TOTAL_1="124" TOTAL_2="118" VAR="0.6834609075997813" WEIGHT="13.836074216081121"/>
<DICH_DATA CI_END="3.853178008845796" CI_START="0.38042080544099655" EFFECT_SIZE="1.2107142857142856" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5858190729822952" LOG_CI_START="-0.41973573926056934" LOG_EFFECT_SIZE="0.08304166686086291" ORDER="7269" O_E="0.0" SE="0.5906678742880566" STUDY_ID="STD-van-Koningsveld-2004" TOTAL_1="112" TOTAL_2="113" VAR="0.34888853771597134" WEIGHT="33.603311429450066"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.233863247974938" CI_END="2.498476571157843" CI_START="0.9118976911091603" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5094220803105964" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="22" I2="10.469004679983955" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.3976752813092949" LOG_CI_START="-0.04005388390749049" LOG_EFFECT_SIZE="0.17881069870090222" METHOD="MH" MODIFIED="2016-10-03 15:27:59 +0100" MODIFIED_BY="Ruth Brassington" NO="5" P_CHI2="0.32728278426775037" P_Q="0.5754162728195051" P_Z="0.10931587699162008" Q="0.3137039164053826" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="252" TOTAL_2="239" WEIGHT="100.00000000000001" Z="1.6012756624550928">
<NAME>Death or disability after 1 year</NAME>
<GROUP_LABEL_1>CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.806875956675853" CI_START="0.14096979346825833" DF="0" EFFECT_SIZE="0.9047619047619048" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.7639425489700256" LOG_CI_START="-0.8508739365322062" LOG_EFFECT_SIZE="-0.0434656937810903" MODIFIED="2016-05-12 00:16:34 +0100" MODIFIED_BY="Ruth  Brassington" NO="1" P_CHI2="1.0" P_Z="0.9159696115552691" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="19" WEIGHT="9.297672259893426" Z="0.10551192056661211">
<NAME>Oral regimens</NAME>
<DICH_DATA CI_END="5.806875956675853" CI_START="0.14096979346825833" EFFECT_SIZE="0.9047619047619048" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7639425489700256" LOG_CI_START="-0.8508739365322062" LOG_EFFECT_SIZE="-0.0434656937810903" MODIFIED="2016-05-12 00:16:34 +0100" MODIFIED_BY="Ruth  Brassington" ORDER="1" O_E="0.0" SE="0.9485511970545312" STUDY_ID="STD-Hughes-1978" TOTAL_1="21" TOTAL_2="19" VAR="0.899749373433584" WEIGHT="9.297672259893426"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9394287973623918" CI_END="2.656378351726499" CI_START="0.9295782323494358" DF="1" EFFECT_SIZE="1.5714043059153258" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="20" I2="48.43842674915458" ID="CMP-001.05.02" LOG_CI_END="0.42428993227903583" LOG_CI_START="-0.031714054576387395" LOG_EFFECT_SIZE="0.1962879388513242" MODIFIED="2016-05-12 00:16:43 +0100" MODIFIED_BY="Ruth  Brassington" NO="2" P_CHI2="0.16373084281941652" P_Z="0.09153765057363779" STUDIES="2" TAU2="0.0" TOTAL_1="231" TOTAL_2="220" WEIGHT="90.70232774010658" Z="1.6873417857645667">
<NAME>Intravenous regimens</NAME>
<DICH_DATA CI_END="4.649541722198326" CI_START="1.0603861965305184" EFFECT_SIZE="2.2204301075268815" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="9" LOG_CI_END="0.667410149163372" LOG_CI_START="0.02546406571359732" LOG_EFFECT_SIZE="0.34643710743848466" MODIFIED="2016-05-12 00:16:38 +0100" MODIFIED_BY="Ruth  Brassington" ORDER="1" O_E="0.0" SE="0.37708230710275975" STUDY_ID="STD-GBS-Steroid-1993" TOTAL_1="124" TOTAL_2="118" VAR="0.14219106632994002" WEIGHT="40.83511311310926"/>
<DICH_DATA CI_END="2.250212551555431" CI_START="0.48060287793331713" EFFECT_SIZE="1.0399320305862363" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.3522235428259308" LOG_CI_START="-0.3182136328937153" LOG_EFFECT_SIZE="0.01700495496610775" MODIFIED="2016-05-12 00:16:43 +0100" MODIFIED_BY="Ruth  Brassington" ORDER="2" O_E="0.0" SE="0.39381811573526354" STUDY_ID="STD-van-Koningsveld-2004" TOTAL_1="107" TOTAL_2="102" VAR="0.15509270828127344" WEIGHT="49.867214626997324"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.022422355787503276" CI_END="0.16242062549669856" CI_START="-0.3581548911800624" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.09786713284168193" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2016-10-03 15:27:59 +0100" MODIFIED_BY="Ruth Brassington" NO="6" P_CHI2="0.8809690019888278" P_Q="1.0" P_Z="0.4611597895915235" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="232" TOTAL_2="223" UNITS="" WEIGHT="100.0" Z="0.7369384440682305">
<NAME>Disability grade change after 6 months</NAME>
<GROUP_LABEL_1>CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.269916885459695" CI_START="-0.42991688545969514" EFFECT_SIZE="-0.08000000000000007" ESTIMABLE="YES" MEAN_1="-2.4" MEAN_2="-2.32" ORDER="1" SD_1="1.52" SD_2="1.25" SE="0.17853230376669918" STUDY_ID="STD-GBS-Steroid-1993" TOTAL_1="124" TOTAL_2="118" WEIGHT="55.332167895795365"/>
<CONT_DATA CI_END="0.26945412276260755" CI_START="-0.5094541227626077" EFFECT_SIZE="-0.1200000000000001" ESTIMABLE="YES" MEAN_1="-2.41" MEAN_2="-2.29" ORDER="2" SD_1="1.47" SD_2="1.43" SE="0.1987047342882686" STUDY_ID="STD-van-Koningsveld-2004" TOTAL_1="108" TOTAL_2="105" WEIGHT="44.667832104204635"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.3163039571983415" CI_END="0.29043206064153243" CI_START="-0.2299328041029227" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.030249628269304864" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2012-05-09 21:47:46 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.5178074053104351" P_Q="1.0" P_Z="0.8197460775536519" Q="0.0" RANDOM="NO" SCALE="1.7" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="242" TOTAL_2="229" UNITS="" WEIGHT="99.99999999999999" Z="0.2278715800025351">
<NAME>Disability grade change after 12 months</NAME>
<GROUP_LABEL_1>CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3664616393100313" CI_START="-0.5464616393100316" EFFECT_SIZE="0.4099999999999999" ESTIMABLE="YES" MEAN_1="-1.91" MEAN_2="-2.32" ORDER="1" SD_1="1.14" SD_2="1.83" SE="0.4879995994081926" STUDY_ID="STD-Hughes-1978" TOTAL_1="21" TOTAL_2="19" WEIGHT="7.399814380984868"/>
<CONT_DATA CI_END="0.4366746539365809" CI_START="-0.2566746539365803" EFFECT_SIZE="0.0900000000000003" ESTIMABLE="YES" MEAN_1="-2.57" MEAN_2="-2.66" ORDER="2" SD_1="1.53" SD_2="1.21" SE="0.17687807361314087" STUDY_ID="STD-GBS-Steroid-1993" TOTAL_1="124" TOTAL_2="118" WEIGHT="56.32636920603824"/>
<CONT_DATA CI_END="0.2919976100328718" CI_START="-0.5719976100328721" EFFECT_SIZE="-0.14000000000000012" ESTIMABLE="YES" MEAN_1="-2.64" MEAN_2="-2.5" ORDER="3" SD_1="1.54" SD_2="1.49" SE="0.22041099399806013" STUDY_ID="STD-van-Koningsveld-2004" TOTAL_1="97" TOTAL_2="92" WEIGHT="36.273816412976885"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.9389151094882955" CI_END="2.184924752557265" CI_START="0.5918135532829605" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.137131514586949" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" I2="31.947677102241077" I2_Q="35.43288529064977" ID="CMP-001.08" LOG_CI_END="0.3394364847334968" LOG_CI_START="-0.22781509316558327" LOG_EFFECT_SIZE="0.05581069578395681" METHOD="MH" MODIFIED="2016-10-03 15:27:59 +0100" MODIFIED_BY="Ruth Brassington" NO="8" P_CHI2="0.23005029583376713" P_Q="0.21331670048247453" P_Z="0.6997384843147826" Q="1.5487760363793768" RANDOM="NO" SCALE="175.12" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="251" TOTAL_2="239" WEIGHT="100.00000000000001" Z="0.385673510486516">
<NAME>Proportion of participants who relapsed</NAME>
<GROUP_LABEL_1>CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="115.72929405345836" CI_START="0.3499189042826871" DF="0" EFFECT_SIZE="6.363636363636363" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="2.0634433039428495" LOG_CI_START="-0.4560325942307859" LOG_EFFECT_SIZE="0.8037053548560318" NO="1" P_CHI2="1.0" P_Z="0.21113690556014042" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="19" WEIGHT="3.3080224275623293" Z="1.2504454206858584">
<NAME>Oral regimens</NAME>
<DICH_DATA CI_END="115.72929405345836" CI_START="0.3499189042826871" EFFECT_SIZE="6.363636363636363" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0634433039428495" LOG_CI_START="-0.4560325942307859" LOG_EFFECT_SIZE="0.8037053548560318" ORDER="1" O_E="0.0" SE="1.479952614194029" STUDY_ID="STD-Hughes-1978" TOTAL_1="21" TOTAL_2="19" VAR="2.1902597402597404" WEIGHT="3.3080224275623293"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3138685351537438" CI_END="1.9103581538740315" CI_START="0.4807381543555164" DF="1" EFFECT_SIZE="0.9583225203716198" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" I2="23.888884371297934" ID="CMP-001.08.02" LOG_CI_END="0.2811147963940824" LOG_CI_START="-0.3180914082052701" LOG_EFFECT_SIZE="-0.01848830590559384" NO="2" P_CHI2="0.25169555992856174" P_Z="0.9037321759468838" STUDIES="2" TAU2="0.0" TOTAL_1="230" TOTAL_2="220" WEIGHT="96.69197757243768" Z="0.12094805905540278">
<NAME>Intravenous regimens</NAME>
<DICH_DATA CI_END="5.541993075520783" CI_START="0.5004155111373992" EFFECT_SIZE="1.6653225806451613" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7436659788144928" LOG_CI_START="-0.3006692371541233" LOG_EFFECT_SIZE="0.22149837083018475" ORDER="1" O_E="0.0" SE="0.6134476754026574" STUDY_ID="STD-GBS-Steroid-1993" TOTAL_1="124" TOTAL_2="118" VAR="0.3763180504569242" WEIGHT="25.8875744594209"/>
<DICH_DATA CI_END="1.669088245153823" CI_START="0.2934295976393773" EFFECT_SIZE="0.6998284734133791" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.2224792985547601" LOG_CI_START="-0.5324960818930283" LOG_EFFECT_SIZE="-0.15500839166913413" ORDER="2" O_E="0.0" SE="0.4434762756634367" STUDY_ID="STD-van-Koningsveld-2004" TOTAL_1="106" TOTAL_2="102" VAR="0.19667120707631253" WEIGHT="70.80440311301678"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="25.23143888838264" CI_END="1.0262744950322011" CI_START="0.6041905876618974" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7874423091604378" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="105" I2="72.25683390088774" I2_Q="85.88958180855904" ID="CMP-001.09" LOG_CI_END="0.011263535954891938" LOG_CI_START="-0.21882604463430372" LOG_EFFECT_SIZE="-0.10378125433970592" METHOD="MH" MODIFIED="2016-10-03 15:27:59 +0100" MODIFIED_BY="Ruth Brassington" NO="9" P_CHI2="6.90337503033378E-4" P_Q="9.292634641977493E-5" P_Z="0.0770487975034685" Q="21.260886525813437" RANDOM="NO" SCALE="23.13" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="944" TOTAL_2="924" WEIGHT="400.0" Z="1.7680724199274434">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>CS</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.0212030867203428" CI_END="1.0360545567720445" CI_START="0.5220780092186974" DF="1" EFFECT_SIZE="0.7354599244292709" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="60" I2="50.52451648376283" ID="CMP-001.09.01" LOG_CI_END="0.015382625178716587" LOG_CI_START="-0.2822645995993025" LOG_EFFECT_SIZE="-0.133440987210293" NO="1" P_CHI2="0.15511659247554854" P_Z="0.07885318697076263" STUDIES="2" TAU2="0.0" TOTAL_1="236" TOTAL_2="231" WEIGHT="100.0" Z="1.757379254509741">
<NAME>New infection treated with antibiotics</NAME>
<DICH_DATA CI_END="1.559158692409069" CI_START="0.580804970010236" EFFECT_SIZE="0.9516129032258065" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="25" LOG_CI_END="0.1928903202755205" LOG_CI_START="-0.23596967598773982" LOG_EFFECT_SIZE="-0.021539677856109666" ORDER="1" O_E="0.0" SE="0.25191448469625816" STUDY_ID="STD-GBS-Steroid-1993" TOTAL_1="124" TOTAL_2="118" VAR="0.06346090759978129" WEIGHT="42.37185172585564"/>
<DICH_DATA CI_END="0.9347536188666334" CI_START="0.3555884033468508" EFFECT_SIZE="0.576530612244898" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="35" LOG_CI_END="-0.029302844814269823" LOG_CI_START="-0.4490524109318428" LOG_EFFECT_SIZE="-0.2391776278730563" ORDER="2" O_E="0.0" SE="0.2465629729313249" STUDY_ID="STD-van-Koningsveld-2004" TOTAL_1="112" TOTAL_2="113" VAR="0.06079329962073325" WEIGHT="57.62814827414436"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.14688326011691202" CI_END="3.781795995056932" CI_START="0.36347836023963315" DF="1" EFFECT_SIZE="1.1724337964440061" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="0.5776980975892217" LOG_CI_START="-0.43952143984832237" LOG_EFFECT_SIZE="0.06908832887044962" MODIFIED="2016-10-03 15:27:59 +0100" MODIFIED_BY="Ruth Brassington" NO="2" P_CHI2="0.7015319409069212" P_Z="0.7900568448346544" STUDIES="2" TAU2="0.0" TOTAL_1="236" TOTAL_2="231" WEIGHT="100.0" Z="0.2662367981630595">
<NAME>Gastrointestinal haemorrhage</NAME>
<DICH_DATA CI_END="4.62155672662448" CI_START="0.19594417447457405" EFFECT_SIZE="0.9516129032258065" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6647882880896601" LOG_CI_START="-0.7078676438018793" LOG_EFFECT_SIZE="-0.021539677856109666" ORDER="1" O_E="0.0" SE="0.8063048891495375" STUDY_ID="STD-GBS-Steroid-1993" TOTAL_1="124" TOTAL_2="118" VAR="0.650127574266448" WEIGHT="60.69263567015692"/>
<DICH_DATA CI_END="8.884962090932088" CI_START="0.2577791460009198" EFFECT_SIZE="1.5133928571428572" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9486555791605515" LOG_CI_START="-0.5887522194227128" LOG_EFFECT_SIZE="0.17995167986891938" ORDER="2" O_E="0.0" SE="0.9030809511791498" STUDY_ID="STD-van-Koningsveld-2004" TOTAL_1="112" TOTAL_2="113" VAR="0.815555204382638" WEIGHT="39.30736432984308"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.516179367067459" CI_END="4.1233534705987" CI_START="1.189195438791782" DF="1" EFFECT_SIZE="2.2143787254582805" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="13" I2="60.257205305459856" ID="CMP-001.09.03" LOG_CI_END="0.6152505658832353" LOG_CI_START="0.07525323478167345" LOG_EFFECT_SIZE="0.3452519003324544" NO="3" P_CHI2="0.11268360104778441" P_Z="0.012202297431260277" STUDIES="2" TAU2="0.0" TOTAL_1="236" TOTAL_2="231" WEIGHT="100.0" Z="2.5062393877585807">
<NAME>Diabetes mellitus requiring insulin</NAME>
<DICH_DATA CI_END="3.2030243633601483" CI_START="0.2827225193616257" EFFECT_SIZE="0.9516129032258065" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5055602420770693" LOG_CI_START="-0.5486395977892886" LOG_EFFECT_SIZE="-0.021539677856109666" ORDER="1" O_E="0.0" SE="0.6192422043108669" STUDY_ID="STD-GBS-Steroid-1993" TOTAL_1="124" TOTAL_2="118" VAR="0.38346090759978135" WEIGHT="39.14888362538307"/>
<DICH_DATA CI_END="6.448028713072118" CI_START="1.420811253776068" EFFECT_SIZE="3.0267857142857144" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="8" LOG_CI_END="0.8094269627146854" LOG_CI_START="0.1525363883511157" LOG_EFFECT_SIZE="0.48098167553290055" ORDER="2" O_E="0.0" SE="0.3858607750419461" STUDY_ID="STD-van-Koningsveld-2004" TOTAL_1="112" TOTAL_2="113" VAR="0.14888853771597133" WEIGHT="60.85111637461693"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.024339440659591524" CI_END="0.40928029254662157" CI_START="0.05165280689761789" DF="1" EFFECT_SIZE="0.14539764756663429" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="27" I2="0.0" ID="CMP-001.09.04" LOG_CI_END="-0.38797916677498867" LOG_CI_START="-1.2869060732339181" LOG_EFFECT_SIZE="-0.8374426200044536" NO="4" P_CHI2="0.8760243460091894" P_Z="2.603934600913864E-4" STUDIES="2" TAU2="0.0" TOTAL_1="236" TOTAL_2="231" WEIGHT="100.0" Z="3.6518149863669294">
<NAME>Hypertension</NAME>
<DICH_DATA CI_END="0.6936532716774677" CI_START="0.036263999871767004" EFFECT_SIZE="0.1586021505376344" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.15885756099443082" LOG_CI_START="-1.4405242954850757" LOG_EFFECT_SIZE="-0.7996909282397533" ORDER="1" O_E="0.0" SE="0.752857384192461" STUDY_ID="STD-GBS-Steroid-1993" TOTAL_1="124" TOTAL_2="118" VAR="0.5667942409331147" WEIGHT="45.16024603431531"/>
<DICH_DATA CI_END="0.57468379181676" CI_START="0.031489761128617955" EFFECT_SIZE="0.13452380952380952" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="15" LOG_CI_END="-0.24057105138519294" LOG_CI_START="-1.501830633771731" LOG_EFFECT_SIZE="-0.871200842578462" ORDER="2" O_E="0.0" SE="0.7408701220294764" STUDY_ID="STD-van-Koningsveld-2004" TOTAL_1="112" TOTAL_2="113" VAR="0.5488885377159713" WEIGHT="54.839753965684686"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-10-03 15:28:00 +0100" MODIFIED_BY="Ruth Brassington">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-10-03 15:27:59 +0100" MODIFIED_BY="Ruth Brassington" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwIAAAKWCAYAAAD6PC5ZAABbH0lEQVR42uzdD6RVads4/ockSTIk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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-10-03 15:23:34 +0100" MODIFIED_BY="Ruth Brassington" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAb4AAALaCAIAAADBYqFvAAAqKUlEQVR42u3dsW4jR7qGYQEGDAcM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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-10-03 15:28:00 +0100" MODIFIED_BY="Ruth Brassington" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Corticosteroid (CS) versus control, outcome: 1.1 Disability grade change after 4 weeks.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAzUAAAFgCAMAAAC17qezAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2016-10-03 15:28:00 +0100" MODIFIED_BY="Ruth Brassington" NO="4" REF_ID="CMP-001.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Corticosteroid (CS) versus control, outcome: 1.2 Improvement by &#8805; 1 grades after 4 weeks.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvkAAAGACAMAAAAAp43eAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-10-03 15:27:59 +0100" MODIFIED_BY="Ruth Brassington">
<APPENDIX ID="APP-01" MODIFIED="2016-01-18 14:23:07 +0000" MODIFIED_BY="Angela A Gunn" NO="1">
<TITLE MODIFIED="2016-01-18 12:40:01 +0000" MODIFIED_BY="Angela A Gunn">Cochrane Neuromuscular Register (CRS) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-01-18 14:23:07 +0000" MODIFIED_BY="Angela A Gunn">
<P>#1 "guillain barre syndrome" [REFERENCE] [STANDARD]<BR/>#2 polyradiculoneuropath* or polyneuropath* or "acute polyradiculoneuritis" or "acute polyneuritis" [REFERENCE] [STANDARD]<BR/>#3 inflammatory NEAR5 neuropath* or inflammatory NEAR5 polyneuropath* [REFERENCE] [STANDARD]<BR/>#4 #1 or #2 or #3 [REFERENCE] [STANDARD]<BR/>#5 MeSH DESCRIPTOR steroids Explode All [REFERENCE] [STANDARD]<BR/>#6 glucocorticoid* or steroid* [REFERENCE] [STANDARD]<BR/>#7 MeSH DESCRIPTOR Anti-Inflammatory Agents Explode All [REFERENCE] [STANDARD]<BR/>#8 anti-inflammatory agent* or antiinflammatory agent* [REFERENCE] [STANDARD]<BR/>#9 prednisone* or prednisolone* or cortisone* [REFERENCE] [STANDARD]<BR/>#10 #5 or #6 or #7 or #8 or #9 [REFERENCE] [STANDARD]<BR/>#11 #4 and #10 [REFERENCE] [STANDARD]<BR/>#12 (#4 and #10) AND (INREGISTER) [REFERENCE] [STANDARD]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2016-01-18 12:40:12 +0000" MODIFIED_BY="Angela A Gunn" NO="2">
<TITLE MODIFIED="2016-01-18 12:39:14 +0000" MODIFIED_BY="Angela A Gunn">CENTRAL (CRSO) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-01-18 12:39:00 +0000" MODIFIED_BY="Angela A Gunn">
<P>#1("guillain barre syndrome"):TI,AB,KY<BR/>#2(polyradiculoneuropath* or polyneuropathy* or "acute polyneuritis" or "acute polyradiculoneuritis"):TI,AB,KY<BR/>#3(inflammatory NEAR5 neuropath* or inflammatory NEAR5 polyneuropathy*):TI,AB,KY<BR/>#4#1 OR #2 OR #3<BR/>#5MESH DESCRIPTOR Steroids EXPLODE ALL TREES<BR/>#6MESH DESCRIPTOR Anti-Inflammatory Agents EXPLODE ALL TREES<BR/>#7(steroid* or glucocortico*):TI,AB,KY<BR/>#8("anti-inflammatory agent*" or "anti-inflammatory agent*"):TI,AB,KY<BR/>#9(prednisone* or prednisolone* or cortisone*):TI,AB,KY<BR/>#10#5 OR #6 OR #7 OR #8 OR #9<BR/>#11#4 AND #10</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2016-10-03 15:27:59 +0100" MODIFIED_BY="Ruth Brassington" NO="3">
<TITLE MODIFIED="2016-10-03 15:27:59 +0100" MODIFIED_BY="Ruth Brassington">MEDLINE (OvidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-01-12 14:17:10 +0000" MODIFIED_BY="Angela A Gunn">
<P>Database: Ovid MEDLINE(R) &lt;1946 to December Week 5 2015&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 randomized controlled trial.pt. (402815)<BR/>2 controlled clinical trial.pt. (89885)<BR/>3 randomized.ab. (300110)<BR/>4 placebo.ab. (153924)<BR/>5 drug therapy.fs. (1807402)<BR/>6 randomly.ab. (212708)<BR/>7 trial.ab. (308971)<BR/>8 groups.ab. (1348986)<BR/>9 or/1-8 (3423544)<BR/>10 exp animals/ not humans.sh. (4169575)<BR/>11 9 not 10 (2914775)<BR/>12 guillain barre syndrome.tw. or Guillain-Barre Syndrome/ (7017)<BR/>13 POLYRADICULONEUROPATHY/ or POLYNEUROPATHIES/ (8124)<BR/>14 (acute polyradiculoneuritis or acute polyneuritis).mp. (176)<BR/>15 (inflammatory adj5 neuropath$3).tw. (1916)<BR/>16 (inflammatory adj5 polyneuropath$3).tw. (1515)<BR/>17 or/12-16 (15109)<BR/>18 steroid$.tw. or exp steroids/ (851802)<BR/>19 exp Anti-inflammatory Agents/ or anti-inflammatory agent$.tw. (438813)<BR/>20 exp Glucocorticoids/ or glucocorticoid$.tw. (193542)<BR/>21 (prednisone$ or prednisolone$ or cortisone$).mp. (102536)<BR/>22 or/18-21 (1077345)<BR/>23 11 and 17 and 22 (612)<BR/>24 remove duplicates from 23 (606)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2016-10-03 15:27:59 +0100" MODIFIED_BY="Ruth Brassington" NO="4">
<TITLE MODIFIED="2016-10-03 15:27:59 +0100" MODIFIED_BY="Ruth Brassington">Embase (OvidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-01-18 12:35:07 +0000" MODIFIED_BY="Angela A Gunn">
<P>Database: Embase &lt;1980 to 2016 Week 02&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------</P>
<P>1 crossover-procedure.sh. (45414)<BR/>2 double-blind procedure.sh. (124985)<BR/>3 single-blind procedure.sh. (21252)<BR/>4 randomized controlled trial.sh. (388894)<BR/>5 (random$ or crossover$ or cross over$ or placebo$ or (doubl$ adj blind$) or allocat$).tw,ot. (1207245)<BR/>6 trial.ti. (190167)<BR/>7 controlled clinical trial/ (391213)<BR/>8 or/1-7 (1458199)<BR/>9 exp animal/ or exp invertebrate/ or animal.hw. or non human/ or nonhuman/ (21940450)<BR/>10 human/ or human cell/ or human tissue/ or normal human/ (16517365)<BR/>11 9 not 10 (5455817)<BR/>12 8 not 11 (1294364)<BR/>13 limit 12 to embase (1068750)<BR/>14 guillain barre syndrome.tw. or Guillain Barre Syndrome/ (12954)<BR/>15 acute polyradiculoneuritis.mp. or acute polyneuritis.tw. (184)<BR/>16 Polyneuropathies/ or Polyradiculoneuropathy/ (9896)<BR/>17 (inflammatory adj5 neuropath$3).tw. (2977)<BR/>18 (inflammatory adj5 polyneuropath$3).tw. (2375)<BR/>19 or/14-18 (24802)<BR/>20 exp Steroid/ (1198754)<BR/>21 (steroid$ or glucocorticoid$).mp. (419452)<BR/>22 steroid therap$.tw. or Steroid Therapy/ (28896)<BR/>23 Anti-inflammatory Agents.mp. or Antiinflammatory Agent/ (54431)<BR/>24 exp Immunosuppressive Agent/ (592965)<BR/>25 (prednisone$ or prednisolone$ or cortisone$).mp. (259880)<BR/>26 or/20-25 (1567398)<BR/>27 13 and 19 and 26 (350)<BR/>28 remove duplicates from 66 (349)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2016-08-08 16:40:44 +0100" MODIFIED_BY="KLJ " NO="5">
<TITLE MODIFIED="2016-08-08 16:40:44 +0100" MODIFIED_BY="KLJ ">Trials registry search terms</TITLE>
<APPENDIX_BODY MODIFIED="2016-01-27 21:50:47 +0000" MODIFIED_BY="Angela A Gunn">
<P>Guillain Barre syndrome</P>
<P>ClinicalTrials.gov - 30 </P>
<P>WHO international Clinical trials Registry - 33 references to 29 studies</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;8 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="130">
<FLOWCHARTBOX TEXT="&lt;p&gt;8 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;8 studies included in the previous review&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;No relevant studies&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;ClinicalTrials.gov - 30 studies&lt;/p&gt;&lt;p&gt;WHO ICTRP - 33 references to 29 studies&lt;/p&gt;"/>
</FLOWCHARTBOX>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;212 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;248 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>